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CHAPTER 1. GENERAL INTRODUCTION 
Abstract 
 Avian paramyxovirus serotype-1 (APMV-1) is capable of infecting a wide range of 
avian species leading to a broad range of clinical signs.  Ease of transmission has allowed the 
virus to spread world-wide with varying degrees of virulence depending on the virus strain 
and host species.  Classification systems have been designed to group isolates based on their 
genetic composition.  The genetic composition of the fusion gene cleavage site plays an 
important role in virulence.  Presence of multiple basic amino acids at the cleavage site 
allows enzymatic cleavage of the fusion protein enabling virulent viruses to spread 
systemically.  Diagnostic tests, including virus isolation, real-time reverse-transcription 
polymerase chain reaction and sequencing, are used to characterize the virus and identify 
virulent strains.  Genetic diversity within APMV-1 demonstrates the need for continual 
monitoring for changes that may arise requiring modifications to the molecular assays to 
maintain their usefulness for diagnostic testing.    
Introduction 
 Avian paramyxovirus serotype-1 (APMV-1) is a member of the family 
Paramyxoviridae and is the causative agent of virulent Newcastle disease (vND) [1,2].  The 
virus is able to infect all orders of avian species and virulent strains can cause significant 
clinical signs.  Due to the extensive range of susceptible hosts, the virus has been able to 
establish itself world-wide.  Infection by virulent strains has resulted in several panzootics 
since 1926 [1-3].  This disease can have devastating effects on the poultry industry due to the 
high morbidity and mortality associated with virulent strains of the virus [4-6].  Clinical signs 
of vND include drop in egg production, respiratory distress, listlessness, weakness and 
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central nervous system signs [2].  Vaccination programs exist within the United States (U.S.), 
but the virus continues to replicate upon infection and can spread from infected vaccinated 
flocks.  Currently the U.S. is free of vND, but introduction of the disease continues to be a 
major concern for the agricultural community [2].   
 Illegal importation of infected birds is one of the major modes of vND introduction 
into the U.S [2].  Diagnostic testing and rapid detection are important steps to prevent an 
outbreak of the disease.  Real-time reverse transcription polymerase chain reaction (rRT-
PCR) is a rapid diagnostic test for detection of APMV-1 RNA.  Virus isolation in 
embryonating chicken eggs is the “gold standard” method of virus identification but can 
require 5 to 10 days to obtain an isolate.  The current United States Department of 
Agriculture (USDA) validated rRT-PCR assay used at the National Veterinary Services 
Laboratories (NVSL) is designed to detect the matrix gene of most strains of APMV-1 [4,7-
10].  Studies have shown that some strains of APMV-1 such as lineage 6 (class I) viruses and 
some pigeon paramyxoviruses (PPMV-1) are not detected by the primer/probe set used in 
this assay [7,8]. 
 The matrix rRT-PCR assay is able to detect APMV-1 RNA within 3 hours of sample 
receipt in the laboratory.  The NVSL uses this as an important screening assay allowing for a 
quick turn-around time for reporting results.  Lack of detection by the matrix assay can result 
in a 7 to 14 day delay in reporting detection of the virus.  Development of an rRT-PCR assay 
that can detect a broad range of APMV-1 will increase the diagnostic capability of the NVSL 




 When APMV-1 RNA is detected by the matrix rRT-PCR assay, additional testing is 
required for that specimen to determine if the RNA originated from a virulent strain.  The 
USDA validated fusion gene rRT-PCR assay is a pathotyping assay used to detect strains of 
vNDV.  This assay allows for rapid identification of vNDV also within 3 hours of sample 
receipt.  The fusion gene rRT-PCR assay used at the NVSL and the NAHLN laboratories is 
also limited in the strains of vNDV it is able to detect.  Cormorant vNDV and most strains of 
PPMV-1 are not detected using this fusion gene assay [7,11].  Although cormorant vNDV 
and PPMV-1 are not highly infective to poultry, rapid detection is still important in 
diagnosing APMV-1 infection.  Development of an rRT-PCR assay specific for these strains, 
would allow laboratories to easily distinguish cormorant vNDV or PPMV-1 from strains of 
vNDV that are highly contagious to poultry.  
Dissertation Organization 
 This dissertation begins with a general introduction and literature review of avian 
paramyxovirus serotype-1.  That is followed by three research papers organized according to 
the publication format of the Avian Diseases journal and the Journal of Virological Methods.  
General conclusions and acknowledgements will be found at the end of the dissertation.  The 
literature review has been accepted for publication by the Veterinary Medicine International 
online journal.  The first research paper has been accepted to the Avian Diseases journal and 







CHAPTER 2. LITERATURE REVIEW 
Classification 
 There are 9 serotypes of avian paramyxovirus (APMV-1 to APMV-9) capable of 
infecting avian species [2,12-14].  Newcastle disease virus (NDV) falls into the avian 
paramyxovirus serotype 1 (APMV-1).  APMV-1 is a member of the order Mononegavirales 
in the family Paramyxoviridae [2,12,15,16].  This family is broken down into two 
subfamilies; the Paramyxovirinae and Pneumovirinae.  The paramyxovirus family includes 
many significant human and animal pathogens that cause severe disease such as morbilli 
virus, mumps virus, Hendra, Nipah, human respiratory syncytial virus, human parainfluenza 
viruses 1-4, parainfluenza virus 5, Sendai virus and ND virus.  Rearrangement of the family 
Paramyxoviridae by the International Committee on the Taxonomy of Viruses in 1993 
placed APMV-1 in the genus Rubulavirus.  Since that time differences among the family 
Paramyxoviridae lead to development of a new genus Avulavirus [2].  
 The Paramyxovirinae and Pneumovirinae subfamilies differ by several distinct 
characteristics.  Morphologically, pneumoviruses have narrower nucleocapsids and the 
genome encodes more proteins than paramyxoviruses [15-18].  Pneumoviruses encode a 
unique small hydrophobic (SH) protein which is expressed as a type II integral membrane 
protein [15,16].  The protein locates to the plasma membrane and becomes packaged as part 
of the envelope upon release of progeny virion.  These viruses also encode accessory proteins 
NS1 and NS2 along with two M2 matrix proteins which differ from the matrix protein of 
paramyxoviruses.  Antigenic sites of paramyxoviruses are capable of cross-reacting and are 
unique from antigenic sites found on the surface of pneumoviruses [17,18].  The 
hemagglutinin-neuraminidase (HN) surface glycoprotein protein of paramyxoviruses is 
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capable of both hemagglutination and neuraminidase activities while the surface glycoprotein 
(G) of pneumoviruses does not have the neuraminidase function.  
 APMV-1 has a gene map structure similar to Rubulaviruses which is the reason for 
the initial classification [15,16].  Further analysis discovered that unlike other Rubulaviruses, 
APMV-1 lacks a C protein, a small hydrophobic (SH) protein and the phosphoprotein (P) is 
relatively small [15,16,19].  The intergenic region is also variable compared to other 
Rubulaviruses.  Some features such as nucleotide sequence identity at the conserved genomic 
termini and RNA editing make it appear similar to Respiroviruses.  The nucleotide sequence 
does not align with Rubulaviruses nor Respiroviruses leading to the new classification under 
the genus Avulavirus.  
 Two different classification schemes for NDV are used to group isolates based on 
genetic analysis [6,8,14,20,21].  Differences in groupings arise between the two classification 
methods and either can be used based on preference.  One classification proposed by Aldous 
et al. is based on genotypes or genetic lineages grouped under serotype 1 (APMV-1) [21].  
This grouping scheme divides NDV into six lineages (lineages 1 to 6) [12].  Sub lineages (a 
to d) were created in lineages 3 and 4 while sub lineages (a to e) were formed in lineage 5.  
These genetic groupings are indicated by lineage and sub lineage such as 3a and 3b.  A 
second classification method based on the genomic characterization and sequence analysis of 
the F and L genes groups isolates into either class I or class II as opposed to lineages 
[4,6,8,20,22,23].  Isolates from class I are present in the U.S. Live Bird Markets, domestic 
poultry and wild waterfowl.  Class I is composed of primarily low-virulence isolates but one 
virulent isolate has been included in that classification.  Class I viruses have a worldwide 
distribution and are further divided into nine genotypes.  Isolates grouped in class I have the 
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longest APMV-1 genome at 15,198 nucleotides.  Class I isolates are not usually reported to 
the OIE due to their low virulence designation.   
Isolates causing all four panzootics from 1920 to the present are classified as class II 
[20].  Class II viruses are usually recovered from poultry, pet birds and wild waterfowl.  
Class II viruses are further divided into genotypes I through IX.  Genotypes I through IV and 
IX have slightly shorter genome lengths at 15,186 nucleotides.  These genotypes are 
considered “early” due to their identification between 1930 and 1960.  Genotypes V through 
VIII and X have a medium length genome at 15,192 and are considered “late” due to their 
identification after 1960.  All vNDV are classified as class II except for one isolate which 
caused the Australian outbreak from 1998-2000.  This isolate was determined to originate 
from a low-virulence strain of NDV (LoNDV) which increased in pathogenicity after 
circulating through poultry [4,6,20].  This may explain the classification in class I where all 
other isolates are LoNDV.   
LaSota, B1 and Villegas-Glisson/University of Georgia (VG/GA) vaccine virus 
strains are classified as class II, genotype II [6,23].  The velogenic neurotropic NDV 
(vnNDV) Chicken/Texas GB/1948 is also a member of genotype II indicating the broad 
range of isolates which can be assigned to one genotype.  Genotypes V through VIII consist 
of only vNDV isolates and have a worldwide distribution.  The 1971 and 2002 California and 
1971 and 1993 Florida outbreaks were caused by genotype V [6,11,23].  Cormorant vNDV is 
classified under genotype V while PPMV-1 is classified under sub-genotype VIb.  All other 





Discovery of Avian Paramyxovirus Serotype-1 
 The virulent form of NDV was first discovered in Java, Indonesia and Newcastle 
upon Tyne region in England in 1926 [1-3,20,24].  Historical data indicate outbreaks in 
poultry with signs similar to those seen with vND may have been present in Korea prior to 
1926 and also in Scotland as early as 1896.  According to Hanson et al. there are three 
hypotheses to explain the sudden occurrence of vND in South East Asia [25].  First, it is 
possible that vND was endemic in South East Asia and only became a problem when poultry 
became commercialized [1,25].  The second theory is vND was present in bird species living 
in the tropical rain forest and was introduced into poultry by man similar to the way the 
movement of tropical birds spread the disease today.  The third explanation is a major 
mutation occurred in the precursor virus allowing for a change in pathogenicity from low 
virulence to high virulence.  Having the ability to infect all orders of avian species, APMV-1 
has been able to spread throughout the world resulting in four panzootics [1,4,14,26-28].  The 
initial panzootic took 20 years to develop spreading very slowly throughout the world [1].  
The United States (US) was likely not involved in the first panzootic but was not so lucky 
during the second panzootic.  The second outbreak spread at a much faster rate, taking only 4 
years to spread throughout the world.  Globalization and the development of various modes 
of transportation led to the increased rate of disease spread during the second, third and 
fourth panzootics occurring in 1960, the late 1970s and the 1980s respectively. 
 The term “Newcastle disease” was coined by Doyle as a temporary name to 
distinguish it from other diseases at the time [1,2].  The name was never changed, but 
APMV-1 has become an alternative term used interchangeably with NDV [4,8].  Despite 
being a synonym for APMV-1, the term “NDV” has recently evolved to describe the more 
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virulent forms of the disease while APMV-1 encompasses all strains of serotype 1 including 
asymptomatic, low-virulence and highly virulent strains.  Substantial evolution of APMV-1 
led to the formation of a separate clade of virulent NDV discovered in 2003 [11].  A virulent 
strain of NDV emerged between 1995 and 2000 affecting double-crested cormorants in 
Canada.  This strain causes significant mortality in juvenile cormorants and poses a risk to 
other avian species including poultry.  
 Pigeon paramyxovirus-1 (PPMV-1) is another strain of APMV-1 which originated in 
pigeons [1,3,26].  This variant of NDV was discovered in the Middle East during the third 
panzootic in the 1970s. Like the NDV mentioned previously, this virus has spread easily and 
now has a global distribution.  In 1984 the virus spread from pigeons into domestic poultry in 
Great Britain.  Contamination of feedstuffs with pigeon feces lead to 23 outbreaks in 
commercial chickens.  These outbreaks indicated the virus had the ability to replicate and 
cause infection in other avian species.  The disease was no longer limited to feral pigeons and 
could be a source of economic loss.  PPMV-1 disease in pigeons has been an ongoing 
panzootic since the 1980s [1,2].  It remains an endemic disease in several countries due to 
lack of vaccination, housing methods and the sport of pigeon racing.  
World Distribution 
 The World Organization for Animal Health (Office International des Epizooties, OIE) 
defines reportable NDV as an APMV-1 infection in birds which meets the following criteria 
for determining virulence: the intracerebral pathogenicity index (ICPI) in day-old chicks is 
greater than or equal to 0.7 or the carboxyl (C-) terminus of the F2 protein contains multiple 
basic amino acids and phenylalanine at residue 117 of the F1 protein N-terminus [1-
3,7,29,30]. The presence of at least three lysine or arginine residues between positions 113 
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and 116 defines the term “multiple basic amino acids”.  It is difficult to track the geographic 
distribution of vND throughout the world due to limited reporting to the OIE.  Some 
countries only report when the disease is present in commercial poultry and not when it 
erupts in backyard flocks. Use of live vaccines can also interfere with the ability to 
distinguish current infections with vaccinations in part due to the variety of strains used in 
live virus vaccines.  
 Epizootics continue to occur on a regular basis in Central and South America, Africa 
and Asia, while sporadic epizootics occur in Europe [1].  An increase in outbreaks in 
Western Europe began in the 1990s. Several strains were shown to be responsible for these 
outbreaks through phylogenetic and antigenic evaluations. Backyard poultry continues to be 
commonly infected in European countries including outbreaks in 1991-1995 and 2000.  The 
following outbreaks occurred between 1995 and 1999: 18 in Denmark, 27 in Northern 
Ireland, two in Finland, one in Sweden, one in the Republic of Ireland and one in Norway.  
Several outbreaks have occurred in Australia, including one in 1932, 1998, 1999 and 2000.  
The outbreaks in the Republic of Ireland (1990) and Australia (1998-2000) were shown to 
originate from an increase in virulence after replication of a low virulence strain in poultry 
[4,6,20].  In 2008 outbreaks were reported in the Dominican Republic, Belize, Peru, Finland, 
Germany and Japan [6].  Despite lack of reporting to the OIE, NDV remains an endemic 
disease in parts of Africa and Asia.  
Outbreaks in the U.S. 
 A disease termed “pneumoencephalitis”, serologically indistinguishable from APMV-
1, was discovered in the U.S. in the 1930s [1,2,23].  As panzootics of the disease occurred, 
the importation of caged and exotic birds into California caused outbreaks in the 1970s [1-
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3,32].  Regulation of importing birds has become strict, reducing the occurrence of the 
disease in the U.S.  Despite importation quarantine procedures, exotic birds are still 
smuggled into the country on a regular basis.  Virulent NDV is often isolated from illegally 
imported and quarantined birds.  In 1991 six states were affected by vND from illegally 
imported pet birds [2].  Fortunately, the disease was not transmitted to poultry during that 
outbreak.   
The practice of fighting cocks has also led to the introduction of vND into the U.S. 
[2].  In 1975, 1998 and 2002-2003 game fowl were implicated as the source of three separate 
outbreaks of vND.  The 2002-2003 outbreak in California caused the most significant 
economic loss resulting in the depopulation of more than 3 million birds on 2,671 premises 
including 21 commercial table-egg layer flocks [2,23,33].  Transportation of infected birds or 
contaminated material, and transmissibility of the disease led to subsequent outbreaks in 
Nevada, Arizona and Texas.  Efforts to eradicate the disease cost the U.S. an estimated $180 
to $360 million.  Coordinated eradication efforts helped to end the outbreak by 2003.  Since 
that time the U.S. has been free of vND in poultry [4].  
 Currently low-virulence strains of APMV-1 are endemic in the U.S. [4,23].  A 
majority of the field isolates are lentogenic but virulent strains of NDV cause outbreaks in 
double-crested cormorants [2,3,11].  Although adult cormorants are considered to be the 
natural reservoir for this strain of vNDV, juvenile cormorants are highly susceptible to the 
disease.  In 1990 and 1992 cormorant vND caused mortality events in double-crested 
cormorants and pelicans.  Isolates from epidemics in the north central U.S. and southern 
California were classified as velogenic neurotropic viruses, meaning these virulent strains 
caused clinical disease of the nervous system [3]. Outbreaks have also occurred as recently as 
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2008 and 2010 [34].  These vNDV strains are usually restricted to cormorants but in 1992 an 
outbreak of cormorant vND occurred in turkeys in North Dakota [2].  Reoccurrence of the 
disease in poultry has not been seen since that time.  Cormorant vNDV is reportable to the 
OIE due to the high ICPI values and presence of multiple basic amino acids at the fusion 
gene cleavage site [11].  All other virulent strains of NDV are considered exotic to the U.S. 
leading to the term “exotic Newcastle disease” (END) [6,23,27].  The California outbreak in 
2002 was one example of the widespread use of the term “END”.  
PPMV-1 was first introduced into the U.S. at the same time as the Great Britain 
outbreak in 1984 [3,26].  In the year following the initial isolation in New York, the NVSL 
collected 34 additional isolates of PPMV-1 primarily from the eastern U.S.  The virus spread 
throughout the U.S. and has been isolated from feral and domestic pigeons since that time.  
Texas and Georgia experienced a severe form of the disease in 1998, leading to concerns of 
an introduction into commercial chickens similar to the outbreaks in Great Britain.  Up to this 
point, natural transmission of PPMV-1 to domestic chickens has not been reported in the 
U.S. [3].  PPMV-1 continues to be endemic in feral and racing pigeons in the U.S. and doves 
have also been shown to harbor the disease.  Pigeons have become the natural reservoir for 
PPMV-1 [11].   
The Agricultural Bioterrorism Protection Act of 2002 established strict guidelines and 
procedures to control the possession, use and transfer of biological agents that pose a threat 
to animal health [33,35,36].  All virulent strains of Newcastle disease are List A biological 
agents classified as Select Agents under the Code of Federal Regulations [6,19,33,35].  Strict 
handling procedure must be followed when working with this agent.  Isolation or acquisition 
of vNDV must be immediately reported to the Animal and Plant Health Inspection Service 
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(APHIS) and/or the Centers for Disease Control and Prevention (CDC).  In order to work 
with vNDV in the U.S. a facility must be registered with either the APHIS or CDC.  Isolation 
of vNDV is reportable to the OIE and can lead to international trade restrictions therefore 
disease free status is needed to maintain poultry exports from the U.S. [1,3,6,8,24].   
Viral Proteins 
APMV-1 is an enveloped, pleomorphic, non-segmented, negative-sense, single-
stranded RNA virus which is approximately 15.2 kb [2,3,15,16,37].  The genome encodes six 
proteins including; the nucleocapsid (NP), phosphoprotein (P), matrix (M), fusion (F), 
hemagglutinin-neuraminidase (HN) and RNA-dependent RNA polymerase (L).  The virion is 
composed of a stable nucleocapsid core consisting of the NP protein bound to the genomic 
and antigenomic RNA [14-16,38,39].  The P and L proteins bind to the nucleocapsid core 
shortly after synthesis to form the ribonucleoprotein (RNP) complex.  This RNP complex 
becomes the template for transcription by the RNA-dependent RNA polymerase L protein.  
The L protein binds the genomic RNA at a 3’ entry site in the RNP complex and transcribes 
the six protein genes using a start-stop mechanism.  In this mechanism the L protein initiates 
transcription and releases the RNP complex after transcribing a number of nucleotides along 
the gene which for the Paramyxoviridae family is always equal to some multiple of six 
nucleotides.  This transcription requirement is referred to as the “rule of six” [14,38].   
Transcription creates a gradient of messenger RNA (mRNA) protein transcripts in 
order from the 3’-NP-P-M-F-HN-L-5’.  Protein gene proximity to the 3’ end results in a 
higher production of the protein.  The Paramyxovirinae subfamily requires the genome 
length to be a multiple of six nucleotides for efficient replication.  The NP subunit must be in 
contact with six nucleotides at a time which is termed the “rule of six” [14,38].  A shift in the 
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NP subunit on the genomic or antigenomic RNA results in a shift in the promoter position 
leading to incorrect or inefficient replication.  
The ND virion contains two types of surface glycoproteins: the F protein and HN 
protein [2,15,16,39-44].  The F protein is a class I fusion glycoprotein which is synthesized 
as a type I integral membrane protein.  When the protein is translated, three identical 
polypeptide chains assemble into homotrimers.  Carbohydrate chains are posttranslationally 
added to the homotrimers which are biologically inactive.  Host proteases must cleave the 
precursor protein in order for it to become biologically active.   
The F protein cleavage site of velogenic and mesogenic strains (including PPMV-1 
and cormorant vNDV) contains a furin recognition site with multiple basic amino acids 
(arginine or lysine) surrounding the glutamine at position 114 (C-terminus of F2 subunit) and 
a phenylalanine at position 117 (N-terminus of F1 subunit) [2,15,16,41,43,44].  Efficient 
cleavage of the F0 protein and virulence of the NDV strain are reliant on the presence of one 
or both arginines at positions 112 and 115 and/or the phenylalanine at position 117.  Host 
ubiquitous intracellular proteases are able to cleave the F protein in the trans-Golgi 
membranes due to the presence of the polybasic amino acids.  Upon arrival at the plasma 
membrane, these F proteins are already in the active state.  After activation the homotrimers 
are transported via exocytosis to the viral surface.  The C-terminal region creates the 
transmembrane domain which anchors the protein in the plasma membrane while the 
globular head containing the fusion peptide extends from the surface of the plasma 
membrane into the extracellular space to initiate fusion with the host cell membrane.  Low-
virulence strains do not have multiple basic amino acids in the F protein cleavage site.  
Instead they have single basic amino acids and a leucine at position 117.  Due to these 
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differences, the F proteins are not cleaved at the trans-Golgi membranes like they are in 
vNDV and mNDV strains.  The F proteins remain in the inactive state when they reach the 
plasma membrane.   
Synthesis of the F protein occurs along the ER as an inactive F0 precursor [43,45].  To 
activate the F protein, F0 must be cleaved to functional F2 and F1 polypeptides to enable 
infectivity of progeny virions.  These polypeptides must remain bound to the viral surface by 
disulfide bonds enabling the virus particles to be infectious.  The two hydrophobic regions of 
the F1 polypeptide are the N-terminal fusion peptide and the transmembrane domain.  The F1 
polypeptide also contains two heptad hydrophobic repeat regions designated HRA and HRB.    
Upon initial translation the F protein folds into a metastable form prior to fusion 
[43,45].  Large scale conformational changes occur once fusion is activated.  These 
conformational changes progress down an energy gradient to form a stable post fusion 
conformation.  Active F1 polypeptide mediates fusion between the viral lipid membrane and 
host cellular membrane.  Membrane fusion allows the viral genome to enter the host cell 
where initiation of viral replication occurs. 
The second surface glycoprotein is a type II integral membrane protein.  The HN 
protein has a transmembrane region which unlike the F protein, is located at the amino-
terminal region of the protein [43,45].  A hydrophobic region about 25 amino acids in length 
anchors the protein in the viral membrane and acts as a signal sequence.  The HN protein 
promotes fusion of the viral and host cell membranes through interaction with the F protein 
[46,47].  It is able to hemagglutinate cells by binding to sialic acid (SA) receptors [43,45,46].  
The neuraminidase of the HN protein can cleave SA structures for viral release after 
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replication.  The HN protein has also been shown to play a role in tissue tropism independent 
of the amino acid sequence of the F protein [46].  
Replication of NDV begins by attachment of the virus to the host cell membrane.  
The HN protein binds to the SA receptors on the surface of the cell membrane bringing the F 
protein closer to the host cell [43,45,46].  The HN interaction with SA receptors is thought to 
initiate the conformational changes needed to activate the F protein.  Figure 1 is a model 
provided by Bissonnette et al., describing the membrane fusion events [45].  During fusion,  
the F1 polypeptide undergoes additional conformational changes which expose the HRA and 
HRB regions [43,45].  The two hydrophobic regions of the F1 polypeptide act to bind the 
viral membrane to the host cell membrane.  The N-terminal fusion peptide attaches to the 
host cell membrane while the transmembrane domain anchors the viral membrane.  A 6-helix 
bundle (6HB) couples the free energy released during protein refolding when the two 
membranes merge.  The final conformational state of the F protein is the most stable form 
and is not reversible [45].  
Membrane fusion occurs at neutral pH but the exact mechanism of fusion activation 
is unknown [39,43,48,49].  The accepted steps during the fusion event begin with docking of 
the viral membrane to the host cellular membrane.  This docking event occurs through 
interaction between the HN protein and SA receptors.  The F protein is activated as the 
membranes approach and upon membrane merging a pore is formed between the membranes 
[39,44,49-51].   
The F protein alone is not sufficient for membrane fusion to occur [39,44,47,49-51].  
Co-expression of the HN attachment protein was originally thought to be required to promote 
fusion.  Attachment of the HN protein to the SA receptors may not be necessary to initiate 
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activation of the F protein.  NDV isolates that have mutations in the attachment function of 
the HN protein have been shown to continue to promote fusion.  It has also been shown that 
lack of co-expression of the HN protein allows for fusion events to occur with some F 
proteins.  The attachment event itself may not support the activation of the fusion process.  
NDV HN mutants have been shown to be unable to promote fusion while the attachment 
function remains intact.  The attachment protein must be from the same virus as the fusion 
protein in order for fusion events to occur [39,44,49-51].  
The NP, P and L proteins also play a role in replication and infectivity.  All three 
proteins are required for viral synthesis [15-18].  The NP protein serves as the site for viral 
RNA synthesis and captures the genomic RNA into the nucleocapsid during replication to 
protect it from degradation.  The concentration of free NP protein within the cell plays a role 
in restricting the rate of transcription and replication.  The P and L proteins are nucleocapsid-
associated proteins and are needed for polymerase-activity.  The P protein is directly 
involved in nascent chain assembly and binds the L protein to the NP-bound template RNA 
to form the RNP complex.  Viral replication relies on all three proteins to produce infective 
virus particles. 
Viral Replication 
Fusion events result in pore formation allowing the viral nucleocapsid complex to 
enter the host cell [2,39,44,49-51].  All viral replication events occur within the host cell 
cytoplasm.  Because the genome is negative-sense RNA, the RNA-dependent RNA 
polymerase (L) is required to enter the cell with the genomic RNA in order for transcription 
to occur.  Positive-sense RNA intermediates are formed which act as mRNA using the host 
cell translation machinery to translate proteins.  Viral proteins are transported to the cell 
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membrane for virion formation.  The host cell membrane becomes modified to form the new 
viral envelope.  The nucleocapsid proteins align within the new membrane to form the RNP 
complex.  The new virus particles are released by budding through the host cell membrane.  
During viral assembly viral glycoproteins may be expressed on the surface of the host cell 
membrane.  Accumulation of the F protein and HN attachment protein on surface of infected 
cells initiates fusion between neighboring cells to form syncytia [44,45,49].  The F protein 
has been shown to be capable of initiating syncytia formation without the aid of the HN 
protein [45,49].   
Transmission 
 The primary route of transmission is either by ingestion of fecal contaminated 
material or inhalation of droplets containing the organism [1-3,24,52].  Viral replication in 
the respiratory tract of infected birds allows for dissemination of the virus during nasal 
discharge.  When the virus reaches the mucous membranes of susceptible birds, the virus is 
likely to reach the upper respiratory tract.  Replication in the respiratory tract of newly 
infected birds allows for the potential to expose more susceptible birds and the virus easily 
spreads through the flock.  The success of this mode of transmission hinges on the 
environment temperature and humidity and the viral load contained in the aerosolized 
droplets.  Outbreaks in England from 1970 to 1971 and Northern Ireland in 1973 were 
attributed to respiratory inhalation of contaminated droplets.  The virus is also able to 
replicate in the intestinal tract which can then be excreted in the feces.  It has been shown 
that large amounts of virus are commonly excreted in the feces of NDV infected birds.   
Several methods of virus transmission have been linked to the introduction of NDV to 
new premises.  Direct ingestion of feed or water contaminated with feces delivers a high 
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virus load to susceptible birds [1,2,24].  This was demonstrated by the PPMV-1 transmission 
to chickens that occurred in Great Britain in 1984.  Importation of sick pet or exotic birds, 
movement of commercial poultry and game birds or the sport of racing pigeons allows for 
dissemination of the virus across vast distances.  A broad range of animals including reptiles 
and humans can be infected with NDV and are able to distribute the virus to other vulnerable 
animals.  The virus particles have been shown to enter the eggshell after it has been laid 
which gives rise to the potential for virus spread during transport of table or hatching eggs.  
Live or attenuated vaccines may also be a source of infection if the virus used to prepare the 
vaccine is not properly killed or the vaccine is contaminated.  Vaccination and insemination 
crews as well as veterinarians have been shown to transmit the disease from farm to farm due 
to improper cleaning and disinfecting of equipment.  
Live bird markets can also contribute to the persistence and spread of the virus.  
These markets may not follow appropriate cleaning and disinfecting techniques which allows 
for the possibility of environmental contamination.  Live birds in the market are exposed to 
birds from multiple sources.  These birds run the risk of disseminating the virus as they leave 
the market.  Low-virulence strains of NDV have been regularly isolated from wild birds by 
the NVSL [53].  Migratory wild birds have been shown to transmit NDV to free range 
poultry through direct contact or by contamination of feed or water [1,2].  In 1997, eleven 
outbreaks of NDV in poultry in Great Britain were linked to movement of wild birds.  
Double-crested cormorants have also been blamed for the spread of cormorant vND to new 
premises during migration.  The virus is able to persist in natural reservoir adult cormorants, 
allowing epidemics to occur in fledgling cormorants which are highly susceptible to this 
strain of NDV [2,34].   
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Biosecurity of commercial poultry facilities is an important step in preventing 
transmission of NDV and large economic loss.  It is recommended that poultry farms and 
hatcheries should not be in close proximity to each other to protect highly susceptible young 
birds [1].  Poultry farms and flock houses should also be spread apart from each other to 
avoid transfer of contaminated material between premises.  Movement of equipment and 
materials between farms should be restricted and subject to thorough cleaning and 
disinfecting.  Humans may also harbor the virus in the conjunctival sac resulting in 
conjunctivitis and possible dissemination of the virus [1,24,52].  It is not advisable for people 
to move between premises unless appropriate biosecurity procedures are followed.  
Separation of farms based on species is important to prevent introduction of exotic diseases 
to new avian species.  The water supply should be clean and should not come from surface 
water where migratory birds have the potential to contaminate the water source.  
Pathogenesis  
The pathogenicity of the virus depends on multiple factors including host species, 
age, immune status, secondary infections, stress, environmental conditions, the amount of 
virus transmitted and the route of transmission but most importantly the strain of the 
infecting virus [1,2].  Chickens are more susceptible than other species while ducks tend to 
show no clinical signs thus waterfowl are considered a natural reservoir for NDV.  Cleavage 
of the F protein during viral replication in the host plays a major role in the virulence of the 
virus [1,2,41,49,54].  Velogenic and mesogenic strains of NDV are able to replicate 
systemically due to the active state of the F protein.  Unfortunately, vNDV and mNDV 
strains cannot be differentiated based on their amino acid sequences at the F protein cleavage 
site.  Due to the lack of multiple basic amino acids in low-virulence strains, the F protein 
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must be cleaved by secretory trypsin-like proteases which are limited to the mucosal 
membranes in the respiratory and gastrointestinal tracts.  Low-virulence strains are not able 
to replicate systemically due to the limited availability of these trypsin-like proteases.  
Examples of vNDV, mNDV and LoNDV cleavage site sequences are shown in Table 1.  
The length of the HN protein has been shown to influence pathogenicity as well 
[13,42].  The HN0 precursor protein is composed of 616 amino acid residues in avirulent 
strains of NDV including Ulster and D26 [42].  This inactive HN0 is converted to an active 
protein by proteolytic cleavage of a few nucleotides at the C-terminus.  The open reading 
frame of other NDV strains includes stop codons upstream resulting in active proteins of 571 
and 577 amino acids in length.  Shortening of the HN active protein plays some role in 
virulence but is not completely understood.  
Upon infection with NDV, macrophages of the immune system of chickens produce 
type-I and type-II interferon (IFN) [3].  Ten genes encode chicken type-I IFN (ChIFN1) 
while only one gene is responsible for chicken type-II IFN (ChIFN2).  NDV is able to 
replicate in these macrophages despite the immune system response.  Peripheral blood 
lymphocytes and heterophils induce apoptosis when infected with the virus.  Macrophages of 
the respiratory system of turkeys infected with NDV show a reduction in phagocytic and 
bacteriocidal abilities [3].  Natural immune stimulation in poultry may not be sufficient to 
control the disease depending on the infecting strain.  Control strategies are needed to 
prevent development of severe disease.  
Clinical Signs 
The incubation period from the time of infection to development of disease varies 
from 2-15 days depending on several factors [2,12].  The pathogenicity of the virus, host 
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species and age, host immune status, secondary infections, stress, environmental conditions, 
the amount of virus transmitted and the route of transmission can all play a role in 
determining the severity of disease and the length of incubation.  Disease severity has led to 
classification of NDV isolates under three distinct pathotypes [1-3,12,54-56].  Infection of 
lentogenic NDV isolates can range from non-apparent to mild respiratory or gastrointestinal 
disease in adult chickens.  When replication is limited to the gastrointestinal tract, the 
infection is often classified as asymptomatic enteric due to lack of respiratory signs.  Young 
susceptible birds may develop a more serious respiratory disease that can lead to death due to 
increased susceptibility to secondary infection.  LoNDV are categorized as lentogenic NDV 
and are commonly used as sources for vaccine production.   Mesogenic (mNDV) isolates are 
considered of intermediate virulence.  Infection is typically systemic and can lead to 
development of a non-fatal respiratory disease.  Drop in egg production can be seen in layers 
infected with mNDV.  Clinical signs of the nervous system rarely develop, but mortality is 
usually low following infection.  Pigeon paramyxovirus isolates usually fall in the mNDV 
classification due to their intermediate virulence and neurologic signs.  
Highly virulent velogenic (vND) viruses are also systemic and can cause high 
morbidity and mortality.  Factors such as species of the infected bird, age, co-infection with 
other organisms, route of exposure, viral dose, stress and immune status of the individual 
determine disease severity [2,12].  Velogenic viscerotropic ND (vvND) causes acute 
infection of the gastrointestinal mucosa resulting in hemorrhagic lesions and death 
[1,2,12,30].  Clinical signs may begin with weakness, increased rate of breathing, listlessness 
and prostration.  During course of infection, green diarrhea, muscular tremors and paralysis 
22 
 
of the extremities may be apparent.  Edema may be seen on the head especially around the 
eyes.  In highly susceptible flocks, mortality can be as high as 100%.  
Velogenic neurotropic NDV (vnNDV) isolates do not replicate in the gastrointestinal 
mucosa like vvNDV [1,2,12,30].  Infection primarily leads to respiratory distress followed by 
neurologic disease.  Drop in egg production is also seen with this strain of vNDV.  Morbidity 
is similar to vvND, around 100% but the mortality rate is lower.  Mortality in adult birds is 
usually only 50% but in young chickens it can be as high as 90%.  Cormorant vNDV falls 
within the vnNDV classification due to the severe neurologic signs and high mortality rate in 
juvenile cormorants [3].  Clinical signs in turkeys may be less severe than those seen in 
chickens.  Game birds are also susceptible and outbreaks occasionally occur in these species.  
Ratites are less susceptible to disease development while waterfowl are usually resistant 
[1,2,12].   
Vaccination   
Vaccination for NDV originated with the use of inactivated infective strains which 
were shown to provide protection in chickens [2,3].  Inability to produce safe and effective 
vaccines resulted in discontinuation of large scale production.  The ability to attenuate 
vNDV, developed by Iyer and Dobson in 1930 enabled mNDV vaccine development [2].  
Inactivated vaccines were also relied upon in the U.S. when NDV was first introduced in the 
1930’s [2,3].  Inactivated vaccines involved adsorbing the virus to aluminum hydroxide.  
These types of vaccines were commonly used in Europe until the third panzootic in the 
1970’s.  The performance of inactivated vaccines was not sufficient during that panzootic so 
vaccination programs implemented the use of live vaccines.  Mesogenic Roakin and milder 
Hitchner B1 and LaSota strains were developed into live virus vaccines and continue to be 
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used today to produce live and inactivated vaccines [1,2,30].  Modern inactivated vaccines 
utilize oil emulsions instead of aluminum hydroxide resulting in more successful vaccines.  
Oil emulsions act as adjuvants to stimulate the inflammatory immune response [40].  
Inactivated vaccines lacking an adjuvant will not induce the early immune response needed 
to stimulate antibody production.  The adjuvant is needed to present the antigen to the 
immune system, localize the antigen to the inoculation site or directly stimulate the innate 
immune response.  Aluminum hydroxide deposits the antigen at the site of inoculation while 
oil emulsions stimulate the immune response directly.  
Vaccination for NDV is practiced widely in the U.S., and like other countries, vaccine 
production is tightly controlled [2,6].  The OIE guidelines for vaccine production specify that 
live and inactivated virus vaccines must be tested extensively [2,30].  The master seeds of 
live virus vaccines must have an ICPI value less than 0.4 if no less than 107 50% mean egg 
infectious dose (EID50) is inoculated in each bird or less than 0.5 if no less than 108 EID50 are 
inoculated in each bird.  Similarly the master seeds of inactivated viruses must have an ICPI 
value less than 0.7 if no less than 108 EID50 are inoculated in each bird.   
Live virus vaccines may be divided into lentogenic and mesogenic groups [1,2,30].  
The immune response has been shown to increase as the pathogenicity of the live virus 
vaccine increases.  To provide the best protection vaccine programs have adopted the method 
of progressive vaccinations which involves successive booster vaccines with increasingly 
virulent strains [1,2,30].  Another method begins with low-virulence live virus vaccination 
followed by successive vaccinations using more virulent inactivated viruses [1,2,30].  This 
method of combining inactivated and live virus vaccines, leads to stimulation of the cell-
mediated, innate and humoral immune responses to improve protection.  Live virus vaccines 
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are usually lyophilized allantoic fluid produced by infecting embryonating chicken eggs.  
The advantages of live vaccines include ease of administration, inexpensive production and 
ease of application.  Live virus stimulates a cell-mediated immune reaction which results in 
rapid protection after vaccination.  Live viruses are able to transmit between birds so 
protection can be spread easily among a flock.  This also results in disadvantages due to the 
potential for live virus vaccines to produce clinical signs in the flock which are again easily 
transmitted.  Maternal antibodies can prevent live virus vaccines from immunizing young 
birds.  Cell-mediated immune response initiated by infection by live virus does not offer 
complete protection against challenge.  This offers an additional disadvantage for live virus 
vaccines.    
Lentogenic live virus vaccines are administered by intranasal inoculation, eye drop, 
or beak-dipping [2,3,30,52].  Administration of mesogenic live virus vaccines is more labor-
intensive and includes wing-web stabbing or intramuscular inoculation.  Addition of 
controlled concentrations of vaccines to drinking water is a popular method of vaccination.  
Sprays and aerosols are also a popular method for vaccine application but the size of aerosol 
particles must be controlled to allow for proper inhalation.  This method is usually reserved 
for secondary doses of vaccines to avoid severe reactions.  Suboptimal vaccinations can 
result in “rolling reactions” where ND may cause disease that spreads between the birds of a 
flock resulting in increasing respiratory disease [6].  It is also possible that introduction of 
LoND from wild birds into a sub-optimally vaccinated flock may result in the same “rolling 
reaction”.  
Inactivated vaccines are produced using the same method as live virus vaccines but 
the virus in the allantoic fluid is inactivated using beta-propiolactone or formalin [2,3,30].  
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An adjuvant (originally aluminum hydroxide and now oil-emulsion) is added to the 
inactivated virus to stimulate the immune system.  Several viruses are currently used to 
produce inactivated vaccines including Ulster 2C, Hitchner B1, LaSota, Queensland/V4, F, 
and Roakin [2,3,20,30].  Administration of inactivated vaccines is limited to intramuscular or 
subcutaneous injection.  Storage of inactivated vaccines is easier than live virus vaccines 
since the viability of the virus does not have to be maintained.  It is labor intensive to 
produce inactivated vaccines due to the steps required for inactivation and testing to ensure 
inactivation was complete.  Oil-emulsion inactivated vaccines can be used in day-old chicks 
because the maternal antibodies do not affect the vaccine efficiency.  There is a 42-day 
withdrawal period between vaccination and slaughter for human consumption in the U.S. that 
poses a problem for broiler chickens due to their short life span.  No matter which type of 
vaccine is used, birds are still able to become infected by NDV and can transmit the disease 
to others [2,5,6].  Because vaccination cannot prevent disease transmission, its role is limited 
to safeguarding the individual bird from significant disease by providing protective 
antibodies that can quickly respond to the introduction of an ND virus [2,5,6].  
The F and HN surface glycoproteins can elicit a protective humoral immune response 
[3,5,30,40,52].  Many researchers are using recombinant viruses to express these proteins for 
vaccine production.  Fowlpox virus, vaccinia virus, pigeon pox virus, Marek’s disease virus, 
retrovirus and baculovirus have all been used as recombinant vectors to express the F and 
HN proteins [3].  A recombinant herpes virus expressing the F and HN proteins has been 
successful in protecting turkeys.  Sakaguchi et al. expressed the F protein of lentogenic D26 
using a recombinant Marek’s disease virus [5,57].  Mori et al. used a recombinant 
baculovirus to express the F protein of D26 and Lee et al. used a recombinant baculovirus to 
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express both the F and HN proteins of LaSota and vvNDV Kr-005/00 [5,58].  These subunit 
marker vaccines can provide effective antibody production while lending the ability to 
distinguish between natural NDV infection and vaccination [5,20].  Research is emerging on 
the development of genotype and antigenically-matched vaccines which are meant to 
eliminate viral shedding upon infection with a strain of the same genotype or antigenic 
characteristics [6].  Naked DNA plasmids are also being developed to express the F protein 
for vaccination [3].  
Vaccination may cause selective pressure leading to the appearance of new strains of 
NDV [6,23].  Mexico and South Korea are experiencing the effects of selective pressure or 
ineffective vaccination.  Both countries have continual outbreaks of vND in backyard flocks 
and have well vaccinated birds with high levels of protective antibodies that develop a drop 
in egg production with the absence of clinical signs.  Vaccination against PPMV-1 in racing 
pigeons is a common practice in many countries.  Exposure to unvaccinated feral pigeons 
opens the possibility of disease transmission.  
Diagnosis/Control  
Clinical signs:  Diagnosis of disease begins with evaluation of clinical signs.  In 
chickens, signs indicative of vND infection include prostration, ruffling of feathers, 
depression, leg and wing paralysis or other neurologic signs along with a high mortality rate 
reaching 100% in fully susceptible flocks [1,2,12].  Clinical signs in the field may not be a 
reliable measure of the virulence of the virus.  Laboratory diagnosis is necessary for 
confirmation and pathotyping of NDV to rule out other diseases which may cause similar 
signs including highly pathogenic avian influenza virus.      
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Pathology:  As previously mentioned, the strain and the route of infection play a 
large role in development of clinical signs and lesions.  Infection with panzootic vvND is 
commonly associated with necrosis of the intestinal wall or lymphoid tissues resulting in 
hemorrhagic lesions in the mucosa of the proventriculus, ceca, duodenum, jejunum and ileum 
[1,2,12,52].  Birds displaying neurologic signs do not have pathologic lesions in the central 
nervous system.  Gross lesions of the respiratory tract may include hemorrhage of the 
respiratory mucosa, airsacculitis and congestion of the trachea but are not always seen.  
Secondary bacterial infection is a significant concern and may lead to thickened air sacs with 
catarrhal or caseous exudates.  Infection in other organs may be marked by hemorrhage in the 
lower conjunctiva, paratracheal edema and necrosis of the spleen.  Laying poultry infected 
with vND may demonstrate flaccid and degenerative ovarian follicles, hemorrhage of 
reproductive organs including the ovarian follicles and egg yolk in the abdominal cavity 
[1,2,12].       
Examination by histopathology also yields a variety of descriptive lesions influenced 
by the virulence of the strain and route of introduction [1,2,12].  Microscopic lesions may 
include cellular infiltration, oedema, hyperaemia and necrosis.  Neurologic lesions are 
comprised of encephalomyelitis with degeneration of the neurons, lymphocyte infiltration 
and hypertrophic endothelial cells.  These lesions are usually found in the cerebellum, 
midbrain, spinal cord, medulla and brain stem.  Complete loss of cilia in the respiratory tract 
can occur within days of infection.  In the early stages of infection, lymphocyte and 
macrophage infiltration is common in the mucosa of the upper respiratory tract along with 
congestion and edema.   
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Virulent strains can cause hemorrhaging of the blood vessels in multiple organs 
especially the intestinal tract [1,2,12]. The serosal and mucosal surfaces show marked 
necrosis in intestinal lymphoid aggregates.  Necrosis can be seen in the cecal tonsils and 
hyperplasia of monocytes is evident in the liver and other organs.  The germinal centers of 
the spleen and thymus show marked focal vacuolation and lymphocyte destruction.  
Hemorrhages can also occur in the heart, gallbladder, skin and eyelids leading to 
conjunctivitis.  Petechiae of the wattle and combs and facial edema are commonly seen 
during infection.  Diagnosis should not be based on pathognomonic lesions or clinical signs 
because these types of signs and lesions are not specific to any strain of NDV.  Some lesions 
may be seen with infection of low-virulence strains and signs may be similar to those seen 
with more virulent strains.  Pathology is a useful tool to guide disease diagnosis but it cannot 
be used solely to diagnose ND considering these types of lesions are not unique to NDV 
infection. 
Serologic techniques:  Detection of antibodies to NDV is primarily used to evaluate 
the immune response to past infection or vaccination [1,2,12,30,31,52].  Generally a higher 
antibody titer will be seen following a more recent infection.  Several diagnostic tests are 
available including virus neutralization in chick embryos, plaque neutralization, 
hemagglutination-inhibition (HI), single radial immunodiffusion, agar gel immunodiffusion 
(AGID) and enzyme-linked immunosorbent assay (ELISA).  The ELISA and HI tests are 
capable of measuring antibody titers.  The ELISA consists of a microtiter plate coated with 
NDV antigen.  Addition of serum containing anti-NDV antibodies creates antigen-antibody 
binding which is detected using a reporter antibody.  An enzyme is conjugated to the reporter 
antibody so when anti-NDV antibodies are present and bound to the NDV antigen, the 
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enzyme bound to the anti-chicken antibodies catalyzes a color change in the well.  This can 
be read by viewing the plate or quantitatively measuring the optical density using a 
spectrophotometer.  Serial dilution of the anti-NDV antibody test serum can be used to 
determine the titer.  
The HI test is also performed in a microtiter plate [12,30,31].  The OIE standard HI 
method employs a V-bottom microtiter plate in which serum test specimens are serially 
diluted in twofold dilutions using phosphate buffered saline (PBS).  A known quantity of 
NDV antigen (usually 4 Hemagglutinating Units) is added to each well and incubated to 
allow antigen-antibody binding. A 1% suspension of red blood cells (RBCs) is added to each 
well and incubated again.  The hemagglutinin protein on the envelope of NDV binds RBCs 
resulting in what is referred to as hemagglutination.  Unbound antigen in the HI test is able to 
hemagglutinate the RBCs in the absence of anti-NDV antibody resulting in a diffuse red 
color throughout the well.  In the presence of anti-NDV antibody, the antigen is not able to 
hemagglutinate the RBCs because the hemagglutinin protein is bound to and blocked by the 
anti-NDV antibody.  The RBCs settle into a distinct pellet on the bottom of the well and 
tilting the plate at a 45° angle will result in a teardrop pattern in wells where the antigen is 
fully inhibited.  The teardrop pattern of each serum sample should be compared to that of a 
known antibody control diluted using the same method described above.   
The NVSL employs a slightly different version of the OIE standard HI test.  U-
bottom microtiter plates are used instead of v-bottom plates [59].  The NDV antigen is added 
to the plate and the serum is diluted directly in the antigen leaving out the need for PBS in 
the test wells.  The RBCs are prepared in a 0.5% suspension instead of the 1% suspension of 
RBCs used in the standard method.  The serum HI titer for both methods is determined by 
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taking the reciprocal of the highest dilution of test serum which is able to completely inhibit 
hemagglutination of the RBCs [1,2,12,30,31,59].  Test serum may cause non-specific 
agglutination of RBCs so adsorption with chicken RBCs to remove serum agglutinins should 
be done on serum prior to testing. 
Virus isolation:  Virus can usually be isolated from tracheal/oropharyngeal swabs, 
fecal or cloacal swabs from live birds or tissues collected from affected organs of dead birds 
[1,2,12,52,60].  Intestinal tissue and trachea are the most likely organs to contain virus but 
other organs demonstrating clinical signs could be used for virus isolation.  PPMV-1 
replicates in the brain causing neurologic signs.  Brain tissue may be used for isolation but it 
is not recommended to pool the brain with any other tissue.  It is also not recommended to 
pool tracheal and fecal tissues [60].  Swabs are collected in viral transport media such as 
brain heart infusion (BHI) broth.  The swab is swirled to release the viral particles into the 
media then wrung out along the inside of the tube so the swab can be removed prior to 
transport to the lab.  Removal of the swab prevents the media from being absorbed to allow 
for more media available for virus isolation and molecular testing.   
Upon arrival in the laboratory, tissues are homogenized to a 20% weight/volume 
suspension in antibiotic media such as BHI broth.  Swab media and tissue homogenates are 
centrifuged to separate the heavier elements from the viral particles in the supernatant.  A 
portion of the swab supernatant is added to an antibiotic mixture and incubated for at least 
one hour to eliminate bacterial contamination.  The swab or tissue suspension is then used to 
inoculate a culture system such as chicken embryo kidney (CEK) cells, chicken embryo 
fibroblast (CEF) cells or specific-pathogen-free (SPF) embryonating chicken eggs 
[1,2,12,60].  The SPF chicken egg is the most commonly used culture system.   
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When SPF eggs are not available, eggs can be used from flocks that do not have 
antibodies to NDV.  Eggs are incubated 9-11 days at 37°C prior to inoculation.  Four to five 
eggs are inoculated into the allantoic cavity with 0.2 mL to 0.3 mL of the antibiotic treated 
suspension and incubated at least four days at 37°C in a humid incubator.  Inoculated eggs 
are examined daily for embryo mortality.  The allantoic/amniotic fluid (AAF) is harvested 
from dead embryos on the same day they die to reduce hemolysis of RBCs within the egg.  
At the end of the incubation period live embryos are chilled at 4°C to kill the embryos and 
the AAF is harvested.  
Presence of live virus in the AAF is determined by the hemagglutination (HA) test 
[1,2,12,61].  As previously described, the hemagglutinin surface glycoprotein of NDV binds 
RBCs resulting in hemagglutination.  In the HA test PBS is added to all wells of a microtiter 
plate and the harvested AAF is serially diluted twofold across the plate.  RBCs are added and 
allowed to incubate approximately 30 minutes and the plate is tilted to evaluate the wells for 
the presence or absence of a teardrop pattern.  Wells with a teardrop formation do not contain 
any or enough viral antigen to agglutinate the RBCs.  Wells exhibiting hemagglutination 
have a diffuse red color throughout the well.  This red color is the result of the agglutination 
of RBCs and antigen forming a lattice.   
Specimens which are not positive for hemagglutinating virus should be passaged 
through embryos at least one more time.  Cormorant vNDV does not always demonstrate the 
ability to hemagglutinate RBCs.  Replacement of chicken RBCs with turkey RBCs may be 
beneficial when testing viral infected AAF isolated from cormorant species.  Even when 
turkey RBCs are utilized, the HA activity of the virus remains low making the HA test 
unreliable for evaluating this strain of NDV.  Bacteria may cause hemagglutination leading to 
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a false positive result.  Contamination of AAF should be evaluated using a culture method 
such as 24 hour incubation on a blood agar plate.  Contaminated AAF can be filtered through 
a 450nm membrane and passaged again in embryos.  
Hemagglutinating virus can be evaluated by the HI test specific for APMV-1 [1-
3,12,58].  U-bottom microtiter plates are set up using a method similar to the one previously 
described for serum specimens.  The unknown AAF is diluted to 4 HA units and added to 
each well in one row of the plate.  A known reference antigen is also added to the wells of 
one row.  APMV-1 positive polyclonal antibody diluted to a known concentration is serially 
diluted twofold in the AAF across the row.  The AAF and antibody are allowed to incubate 
for 30 minutes then a 0.5% suspension of RBCs is added to each well.  Following an 
additional 20 minute incubation, the plate is tilted at a 45° angle and evaluated for tear-drop 
formation using the same method described previously.  Monoclonal antibodies (mAb) can 
also be used in the HI test to identify antigenic groups including PPMV-1, mAb B79 which 
reacts with almost all NDV except class I isolates, other lentogenic mAb’s (such as AVS-1 
and 15C4) and vNDV (mAb 10D11C) [2,3,6,12,26,62].  Additional characterization is 
needed to assess the virulence of the isolate in order to develop control measures during an 
outbreak. 
Characterization:  Historically three in vivo methods have been used to determine 
pathogenicity [2,3,12,30,63,64].  These methods are 1) mean death time (MDT) in 
embryonating chicken eggs, 2) intravenous pathogenicity index (IVPI) and 3) ICPI.  When 
performing the MDT procedure tenfold serial dilutions of clean AAF are prepared and each 
dilution is inoculated into five 9-to-11 day-old embryonating chicken eggs via the allantoic 
sac route [65].  The inoculation time is recorded.  A second group of embryonating chicken 
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eggs is inoculated in the same manner as the first and the inoculation time is again recorded.  
The eggs are incubated at 37°C and candled twice a day, once at the beginning of the day and 
once at the days end.  Candling and incubation continues until all embryos die which may 
require up to seven days.  The minimum lethal dose (MLD) is considered to be the highest 
dilution that killed all 5 embryos.  The time in hours for all five embryos to die for each set 
of the MLD is averaged, giving the MDT.   
The IVPI test requires bacteria-free viral infected AAF with an HA titer greater than 
1:16 [12,30,64].  The AAF is diluted 1:10 in sterile saline and 0.1 ml is intravenously 
inoculated into 10 six-week-old SPF chickens.  Birds are examined daily for a 10 day period 
and each bird is scored according to the following observations: 0 if the bird is normal, 1 if 
the bird demonstrates signs of sickness, 2 if the bird is severely ill and 3 if the bird is dead.  If 
a bird is dead it must be recorded as 3 for each observation for the remainder of the 10 day 
period.  The IVPI is calculated as the mean of each observation for each individual bird over 
the 10 day period.  The index can range from 0.00 meaning no birds became ill or died over 
the observation period, to 3.00 meaning the virus killed all 10 birds in the first 24 hours after 
inoculation.  ICPI is the accepted in vivo method of determining pathogenicity for NDV 
according to OIE standards [1-3,12,30].  As described previously, an ICPI greater than or 
equal to 0.7 is one of the virulence criteria requiring reporting of NDV to the OIE.  Table 1 
shows ICPI, MDT, and IVPI pathogenicity indices for 9 well characterized NDV isolates.   
Any ICPI value above 0.7 is classified in the mesogenic to virulent range [2,3].  
Virulent isolates usually vary from 1.54 to 1.9 (maximum value is 2.0).  Cormorant vNDV 
and PPMV-1 or vNDV isolates recovered from psittacine birds can have a highly variable 
range of ICPI values [2,3,6,26].  These isolates have been shown to have ICPI values from 
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0.69 to 1.45.  These values place them in the mesogenic range which classifies them as select 
agents.  Additional passages of these strains of NDV through embryonating chicken eggs 
may lead to increased ICPI values indicating adaptation to poultry over time.  Viral tropism 
for PPMV-1 during chicken inoculation studies include the heart and brain which is normally 
not seen in infected psittacines or from inoculation with other strains of vNDV [26].  For 
these reasons psittacine origin NDV such as PPMV-1 transmission to poultry continues to be 
highly concerning.   
Velogenic strains of NDV can be classified as either velogenic viscerotropic or 
velogenic neurotropic based on the results of the intracloacal inoculation test [3,28,63,66].  
The intracloacal inoculation test also requires bacteria-free viral infected AAF diluted 1:10 in 
sterile saline.  The cloaca of 4 six-to-eight-week-old SPF chickens are swabbed with the 
diluted inoculum.  Birds are examined daily for a 10 day period.  All dead birds are 
necropsied and scored according to the following observations: +4 when edema of the head 
and neck, hemorrhage in the trachea and hemorrhage and necrosis throughout the 
gastrointestinal tract are present and +3 to +1 when lesions exist in the respiratory and 
intestinal tracts but have decreased severity.  Viruses are determined to be vvNDV if one bird 
has +4 lesions or at least two birds have +2 to +3 lesions.  When birds display neurologic 
signs prior to death, the virus is classified as vnNDV.   
 The need for trypsin in cell culture media has also been used as an indication of 
pathogenicity [2,3,6,23,30].  As previously described, in order for the F protein to become 
active it must be cleaved by secretory trypsin-like proteases.  These types of proteases are 
limited to the mucosal membranes in the respiratory and gastrointestinal tracts.  Low-
virulence strains are not able to replicate systemically due to the limited availability of these 
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trypsin-like proteases.  Virulent strains of NDV are able to replicate systemically due to the 
presence of multiple basic amino acids at the Fusion protein cleavage site which make it 
easier to cleave by non-trypsin-like proteases.  This is also true for in vitro analysis where 
vNDV is able to replicate and cause plaques in cell culture system lacking trypsin-like 
proteases.  Low-virulence strains are limited in the cell culture system in which they are able 
to replicate due to the lack of trypsin-like proteases.  All NDV isolates are able to replicate in 
CEK cells likely due to the presence of trypsin-like proteases.  Cell culture systems like CEF 
and mammalian cell lines must be supplemented with trypsin-like proteases or exogenous 
proteases provided by allantoic fluid, in order for LoNDV to replicate.  
rRT-PCR:  As described in the “Virus Isolation” section, classical diagnostic 
techniques such as virus isolation and chicken pathogenicity testing can be time consuming 
[2,6,24,30,67].  Rapid diagnostic tests such as real-time reverse transcription polymerase 
chain reaction (rRT-PCR) and sequencing to determine pathogenicity greatly reduce the time 
required for implementing control measures.  Molecular diagnostic assays have come a long 
way from conventional PCR followed by gel electrophoresis for amplicon analysis to the 
current methods of rRT-PCR using one-step PCR enzyme kits [68].  RT-PCR assays provide 
quick amplification helping them to become essential diagnostic tools for viral detection.  
The negative sense nature of the NDV RNA requires reverse transcription into 
complimentary DNA (cDNA) prior to RT-PCR amplification.  Reverse transcription of 
single-stranded RNA results in single-stranded cDNA using an RNA-dependent DNA 
polymerase enzyme [68,69].  Advances in enzyme technology allow both steps to be done in 
a single tube on a single PCR instrument.  Several rRT-PCR assays have been developed to 
36 
 
detect different genes of NDV including the Matrix, Fusion and RNA-dependent RNA 
polymerase.   
During rRT-PCR, the reverse transcriptase enzyme becomes activated at 45°C 
initiating reverse transcription of the RNA to cDNA [68-70].  The enzyme is allowed to 
reverse transcribe for approximately 10 minutes.  When ample cDNA has been produced, the 
temperature is brought up to 95°C for an additional 10 minutes which causes the reverse 
transcriptase to become inactivated.  After enzyme inactivation, the instrument enters a 
cycling stage which usually involves advancing through three temperature settings.  The first 
temperature, usually 94°C, causes quick denaturing of the double-stranded cDNA into single-
stranded cDNA.  The second step allows for a set of nucleotide primers usually located 
within less than 500 bases of each other along a gene to anneal to the single stranded cDNA.  
One primer binds the positive sense strand and the other binds the negative sense strand.  In 
real-time PCR a nucleotide probe also binds to its target cDNA sequence located somewhere 
between the two primer sequences during this step.  The temperature of the second step is 
determined by the melting temperature of the less stable primer and the melting temperature 
of the template.  The third step is usually at 72°C, where the polymerase begins at the primer 
binding site and copies the cDNA in the 3’ to 5’ direction along each strand.  This results in 
two sets of double-stranded cDNA from each original cDNA strand.  These three steps, 
denaturing, annealing and amplification are repeated up to 40 or more times resulting in a 
doubling of cDNA during each stage.   
When real-time PCR enters this cycling stage the probe becomes the indicator of 
cDNA amplification.  The TaqMan probe contains a fluorescent reporter dye such as 6-
carboxyfluorescein (FAM), on the 5’ end and a quencher such as the black-hole quencher, 
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located at the 3’ end [68-70].  The proximity of the quencher to the fluorescent reporter dye 
reduces fluorescence from being released by fluorescence resonance energy transfer (FRET) 
through space.  The polymerase moves along the gene extending the primer toward the site 
where the probe is located.  When the polymerase runs into the probe the fluorescent dye is 
cleaved from the probe by the 5’ exonuclease activity of the Taq polymerase.  Since the 
fluorescent dye is no longer in close proximity to the quencher it is allowed to release 
fluorescence.  The probe is subsequently cleaved from the target strand and the polymerase 
copies the remainder of the cDNA strand.  The PCR instrument detects the fluorescence and 
records the accumulation of fluorescence as the cycling stages progress.  The amount of 
fluorescence detected is directly proportional to the amount of fluorophore released during 
the polymerase exonuclease activity.  This is also directly proportional to the number of 
cDNA copies produced during each cycle which is relayed by the instrument as the cycle 
threshold (Ct) value.  The Ct value is determined to be the number of PCR cycles at which 
exponential increase in cDNA copies is detected by the release of fluorescence.  
Detection methods other than TaqMan probes are available and have been utilized for 
NDV rRT-PCR assays. Fluorescent dyes such as SYBR Green or LUX, can be used in RT-
PCR assays without the need for a labeled probe [71].  The LUX dye is used to label one 
primer with a single fluorophore near the 3’ end.  A hairpin at the 3’ end acts to quench the 
fluorescence which is then released when the primer binds the template DNA.  SYBR Green 
intercalates into dsDNA and fluorescence is released as the dsDNA melts during each RT-
PCR cycle.  The amount of fluorescence is proportional to the concentration of DNA in the 
sample.  Some studies have used SYBR Green in conjunction with melt curve analysis for 
differentiating vNDV from LoNDV [72,73].  Melt curve analysis employs intercalating dyes 
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such as SYBR Green or LUX fluorogenic primers to measure the change in fluorescence 
during each cycle which can then be plotted against the melting temperature (Tm) [71-73].  
Virulent and low-virulence strains have differences in GC content, sequence composition, 
base mismatches and amplicon length which contribute to the Tm of each strain.  The 
calculated melt curve can be used to differentiate between strains [72,73].  The melt curve 
must also be analyzed to identify non-specific amplification such as primer-dimers.   
Benefits of melt curve analysis include primer design and cost.  One set of primers 
can be used to differentiate vNDV from LoNDV decreasing the need for multiple primers in 
one assay.  Costs are lower because expensive fluorescent labeled probes are not employed 
and multiple primers do not have to be purchased.  Decrease in specificity is a disadvantage 
of using intercalating dyes such as SYBR Green [71].  These dyes are not bound to a probe 
and therefor have the ability to intercalate non-specifically into any dsDNA present such as 
primer-dimers or non-target amplicons.  Analyzing melting curves for individual isolates can 
be subjective.  The Tm of individual isolates may not vary significantly and can be difficult 
to distinguish between low-virulence and highly virulent strains [72].  TaqMan probes have 
been used extensively in rRT-PCR assays for detection and differentiation of NDV 
[4,7,11,13,29].  These fluorescent labeled probes have the advantage of binding to specific 
regions in the target amplicon which decreases the risk of non-specific fluorescence.  This 
type of detection system may require multiple primer sets and sometimes several different 
TaqMan probes to differentiate between LoNDV and vNDV strains which can be costly 




The USDA validated rRT-PCR assays used at the NVSL and NAHLN laboratories 
detect the M and F genes of NDV.  Both assays utilize TaqMan probes and Taq polymerase 
enzyme.  The M gene assay was designed to detect the highly conserved matrix gene of most 
APMV-1, mainly class II viruses [4,6-8].  This assay is used as a screening tool to detect 
APMV-1 in diagnostic samples or allantoic fluid from inoculated embryos.  The M gene 
assay has been highly successful for APMV-1 detection including vNDV, cormorant vNDV, 
PPMV-1 and most LoNDV.  A recent publication by Kim et al. has shown the M gene assay 
failed to detect 73% of class I isolates between 2004 and 2007 [4,8].  Low-virulence class I 
isolates recovered from waterfowl and live bird markets in the U.S. contained genomic 
variability in the probe binding site causing loss of probe binding.  This lack of detection 
causes significant concern because of the possibility of one of these undetected isolates 
converting from low-virulence to virulent.  The possibility of not detecting a new strain of 
vNDV could lead to an outbreak and significant economic loss.  Development of a new M 
gene assay with the ability to detect a broader range of APMV-1 could reduce the possibility 
of failing to diagnose a new vND outbreak.  
Specimens testing positive by the M gene assay are subsequently tested by the F gene 
rRT-PCR assay.  The F gene assay is designed to only detect virulent strains of APMV-1 by 
binding the F gene cleavage site [6,7,67].  This assay was validated during the California 
END outbreak in 2002-2003 at the NVSL.  Since that time it has been used by the NVSL and 
NAHLN laboratories for vND diagnostic testing.  Recent analysis by Kim et al. indicates 
some PPMV-1 strains are not detected by the F gene assay [6,7].  Mismatches in the probe 
binding site of some strains of PPMV-1 are also to blame for the lack of detection of these 
viruses.  Another publication by Rue et al. indicates that the F gene assay is also unable to 
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detect cormorant vNDV [11].  The inability to detect virulent strains of APMV-1 is of great 
concern because of the potential economic losses associated with the introduction of vND.  
Even though PPMV-1 and cormorant vND are endemic in pigeons and cormorants 
respectively, detection of any strain of vNDV is important in the U.S. because either strain 
may have the potential to infect poultry.  Development of a new F gene assay able to detect 
all strains of vNDV would be beneficial for vND passive surveillance efforts including 
diagnostic testing for avian mortality events and foreign animal disease diagnostic 
investigations. 
Sequencing:  Nucleotide sequencing is used in the diagnostic laboratory to analyze 
the virulence potential of APMV-1 isolates.  Sequencing techniques originated with Sanger 
et al. using the dideoxynucleotide triphosphate (ddNTP) mediated chain termination and 
Maxam et al. using the chemical degradation method [74-76].  Sequencing techniques have 
been rapidly improving since that time and next generation or automated sequencing 
techniques have become standard for laboratory analysis of gene sequences.  In general 
sequencing occurs as follows; template specific primers are used to amplify cDNA to a high 
copy number [77].  The amplified cDNA is added to a second PCR reaction where DNA 
polymerase extends template specific primers by addition of single-fluorescent ddNTPs.  The 
fluorescence of each ddNTP added during chain extension is detected using an automated 
sequencing instrument.  The position of each nucleotide is identified according to the 
distance from the primer.  The identity of the nucleotide in the DNA chain is identified by the 
individual label of each ddNTP incorporated.   
According to the OIE the molecular characteristics of reportable virulent NDV 
include multiple basic amino acids at the carboxyl (C-) terminus of the APMV-1 F2 protein 
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and the presence of phenylalanine at residue 117 of the F1 protein N-terminus [1-3,7,30].  
The presence of multiple basic amino acids allows the F gene of vNDV to be easily cleaved 
by host ubiquitous intracellular proteases present throughout the body [1,2,30,78].  The virus 
is allowed to replicate systemically in any host tissue leading to serious disease development.  
At the NVSL, the presence of multiple basic amino acids is detected by sequencing a short 
region of the F gene encompassing the cleavage site.  The resulting nucleotide sequence is 
converted into an amino acid sequence which is then analyzed manually to evaluate the 
amino acids present directly upstream of the cleavage site.   
One or two pairs of basic amino acids, usually lysine (K) or arginine (R), followed 
directly by phenylalanine at residue 117 indicate a virulent or mesogenic sequence 
[6,13,29,41].  Consensus sequences for virulent and mesogenic strains have been determined 
by Collins et al. to be 112R/K-R-Q-R/K-R-F117 [3,13,41,79].  Molecular analysis at the F gene 
cleavage site cannot differentiate mesogenic and virulent strains.  PPMV-1 isolates have been 
shown to have one of two consensus sequences 112G-R-Q-K-R-F117 or 112R-R-K-K-R-F117 
[6,41,79,80].  Low-virulence strains usually have a single basic amino acid followed by a 
leucine at residue 117.  Consensus sequences for low-virulence strains have been determined 
to be 112G/E-K/R-Q-G/E-R-L117.  Examples of amino acid sequences between positions 112 
and 117 of the FO cleavage site for 9 well characterized APMV-1 strains are shown in Table 
1.  Low-virulence strains are commonly isolated in the U.S. from wild birds, live bird 
markets and poultry vaccinated with live virus.  Fusion gene sequencing analysis is important 
to monitor endemic low-virulence strains to ensure mutations are not present which may lead 
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Figures and Tables 
Figure 1. Model of Membrane Fusion for Paramyxovirus F Protein 
 
Figure 1. (a) The prefusion form of F contains a globular head with the HRA region in 11 distinct sections and the HRB 
region is in a three-helix bundle. The F TM domain is also represented as a three-helix bundle, consistent with the oxidative 
cross-linking data. (b) Upon HN binding to target cells (HN not shown for clarity), F is activated for fusion, and the HRB 
region separates, forming the open-stalk conformation where N-1 peptide can bind to HRB. At this open-stalk stage, the TM 
domain is still thought to be in a three-helix bundle because N-1-HAt can still bind to HRB after the addition of the 
oxidative cross-linker. (c) After formation of the open-stalk conformation, HRA rearranges to form the extended α-helical 
bundle, and the FP is inserted into the target cell membrane (the prehairpin intermediate). (d–e) Finally, the postfusion state 
occurs with the formation of the 6-HB. (d–e and f–i) Lipid intermediates in fusion with the F protein removed for clarity. 
The two bilayers contain an inner and outer leaflet and are separated by the extracellular space. During the process of F 
refolding to form the postfusion form, water is excluded from the extracellular space and the outer leaflets initially merge to 
form the lipid stalk intermediate. The lipids of the bilayers mix, forming the hemifusion intermediate, and then the fusion 
pore forms. F domains: FP (red), HRA (green), globular head (yellow), HRB (blue), TM domain (orange), cytoplasmic tail 
(pink). (From Bissonnette et al., 2009 [45] with permission.) 
Table 1. Examples of ICPI, MDT, IVPI, and Cleavage Site for Some Strains of NDV 
APMV-1 Strain Pathotype ICPI  MDT IVPI Cleavage Site 
Sequence 
Ulster 2C Asymptomatic Enteric 0.0 >150 0.0 112G-K-Q-G-R-L117 
Queensland V4 Asymptomatic Enteric 0.0 >150 0.0 112G-K-Q-G-R-L117 
Hitchner B1 Lentogenic 0.2 120 0.0 112G-R-Q-G-R-L117 
NJ-LaSota Lentogenic 0.4 103 0.0 112G-R-Q-G-R-L117 
NJ-Roakin (Daubney) Mesogenic 1.45 68 0.0 112R-R-Q-K-R-F117 
Beaudette C Mesogenic 1.6 62 1.45 112R-R-Q-K-R-F117 
Texas Gilbert Boney 1948 Velogenic Neurotropic  1.75 55 2.7 112R-R-Q-K-R-F117 
Italien Velogenic 1.85 50 2.8 112R-R-Q-R-R-F117 
England-Herts- 33/56 Velogenic 2.0 48 2.7 112R-R-Q-R-R-F117 
* Information obtained from Diseases of Poultry 12 Ed. Table 3.2p. 81, 3.4 p. 87, Liu et al., 2009 [22] and from NVSL. 
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CHAPTER 3.  AN RRT-PCR ASSAY TO DETECT THE MATRIX GENE OF A 
BROAD RANGE OF AVIAN PARAMYXOVIRUS SEROTYPE-1 STRAINS 
 
Abstract  
The current U.S. Department of Agriculture (USDA)-validated real-time reverse-
transcription polymerase chain reaction (rRT-PCR) assay designed to detect the matrix gene 
of avian paramyxovirus serotype-1 (APMV-1) is the primary screening assay used in the 
United States.  It has previously been shown to be unable to consistently detect all members 
of the class I APMV-1.  Diagnostic testing relies on rRT-PCR to quickly detect APMV-1 in 
wild birds, backyard flocks, live bird markets, commercial poultry and for export testing.  
Limitations of the current USDA assay have raised concerns about the potential for some 
strains of APMV-1 to remain undetected by the primary screening assay.  Mismatches in the 
probe were shown to cause a loss in template binding efficiency, resulting in lack of 
detection by the assay.  Here, we describe the development and analytical validation of a new 
rRT-PCR assay designed to target a highly conserved region of the matrix gene across a wide 
range of APMV-1 strains.  Limit of detection testing revealed a 3 log10 decrease in sensitivity 
for a low-virulence strain when compared to the USDA validated assay.  Conversely, the 
assay showed increased sensitivity for a class I isolate and two virulent strains of APMV-1 
which were not detected by the USDA-validated assay.  The new assay also demonstrated a 
high degree of specificity by the lack of detection of 43 non-APMV-1 viruses.  
Introduction  
 Avian paramyxovirus serotype-1 (APMV-1) is a member of the family 
Paramyxoviridae in the genus Avulavirus (1,2,3,4).  It is a negative sense, single stranded, 
enveloped RNA virus.  It is the causative agent of virulent and low-virulence Newcastle 
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disease (ND).  The APMV-1 genome encodes at least six proteins including the matrix (M), 
fusion (F), hemagglutinin-neuraminidase (HN), nucleocapsid (NP), phosphoprotein (P), and 
the RNA-dependent RNA polymerase (L).  Newcastle disease virus (NDV) has been shown 
to infect more than 200 species of birds and has a worldwide distribution.  There are two 
major divisions according to one system of classification based on the genomic 
characterization and sequence analysis of the F and L genes, (5,6,7,8,9).  Class I, the first 
division, is further apportioned into nine genotypes, and class II includes 10 genotypes.  
Class I consists of primarily low-virulence viruses, frequently isolated from waterfowl and 
live bird markets in the United States.  Class II encompasses both virulent and low-virulence 
viruses.  The majority of vaccine-type low-virulence Newcastle disease viruses (LoNDV) 
found in the United States belong to class II.   
Low-virulence strains of NDV are regularly isolated from wild bird samples tested at 
the National Veterinary Services Laboratories (NVSL) (10).  Currently, the United States is 
free of virulent Newcastle Disease virus (vNDV) (also known as exotic Newcastle Disease) 
but previous outbreaks such as the one in California (2002-03) have led to great economic 
loss for the poultry industry (2,8,9,11).  Quarantine import testing is designed to prevent 
introduction of vNDV through importation of birds.  Foreign animal disease passive 
surveillance is intended to detect the disease in birds with clinical signs, and avian mortality 
events can detect vNDV in wild birds.  All three surveillance methods are necessary to 
prevent an introduction of vNDV into the United States.  The NVSL is a World Organization 
for Animal Health (Office International des Epizooties [OIE]) reference and confirmatory 
laboratory for ND (12).  APMV-1 diagnostic testing is also performed by the National 
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Animal Health Laboratory Network (NAHLN), consisting of 51 state and university 
laboratories (13).   
 Real-time reverse-transcription polymerase chain reaction (rRT-PCR) and virus 
isolation (VI) are the two main diagnostic tests used for detection of APMV-1 
(1,2,4,12,14,15,16).  Virus isolation is the “gold standard” and confirmatory test for rRT-
PCR but can require 5-10 days to obtain an isolate.  Additional time is required for isolate 
characterization and pathogenicity testing.  Real-time RT-PCR is a rapid screening assay 
allowing for detection and pathotyping of APMV-1 directly from diagnostic specimens such 
as tissue, oropharyngeal, or cloacal swabs.  Test results can be obtained within approximately 
3 hr of receipt of the specimens in the laboratory.  Rapid detection and preliminary 
pathotyping of APMV-1 allow for a significant reduction in the time required to respond to 
the induction of disease.  A quick response can have a major impact on the spread of the 
disease from farms or across regions.  A publication by Kim et al. indicates that the current 
U.S. Department of Agriculture (USDA) Matrix rRT-PCR assay used by the NVSL and 
NAHLN to detect the highly conserved M gene of APMV-1 is unable to consistently detect 
several class I viruses due to mismatches between the probe sequence and the genomic target 
site (5,6,17,18).  This demonstrates a weakness in the USDA assay and suggests problems 
may also exist in detection efficiency for more pathogenic strains of APMV-1.  Concerns 
over this deficiency in detection have led to the need for an improved rRT-PCR assay. Here, 
we report the development and analytical validation of an rRT-PCR assay capable of 
detecting the M gene of class I and class II APMV-1, hereafter referred to as the “modified 
assay”.  This study identifies some vNDV and pigeon paramyxovirus type-1 (PPMV-1) 
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strains of APMV-1 that are not detected by the current USDA assay.  These findings 
reinforce the need to implement a new broad-range assay. 
Materials & Methods 
 Isolates and RNA extraction.  Ninety-eight APMV-1 isolates consisting of wild bird 
and poultry origin viruses isolated between 1980 and 2010 along with other historical 
reference viruses were utilized from the NVSL repository.  Two isolates (JN872165 and 
JN872166) were received from the Istituto Zooprofilattico Sperimentale delle Venezie 
(IZSV) Laboratory in Padova, Italy, 31 isolates were acquired from the Instituto Colombiano 
Agropecuario (ICA) Laboratory in Bogota, Colombia (two isolates were used for M gene 
sequencing, JN942059 and JN942060), and two isolates were received from the Servicio 
Agrícola y Ganadero (SAG) in Santiago, Chile (one isolate was used for M gene sequencing, 
JN942061).  Out of the total 103 isolates, 8 were characterized as LoNDV, 35 were vNDV, 
17 were cormorant vNDV, 30 were the PPMV-1 strain of APMV-1 and 13 isolates were 
characterized as class I.  RNA was extracted using a MagMAXTM-96 AI/ND Viral RNA 
Isolation Kit and automated KingFisher extraction instruments.  Briefly, 50 µl of each isolate 
were added to 100 µl viral lysis/binding solution and 20 µl of bead resuspension mix.  
Extracted RNA was washed once in wash solution 1 and twice in wash solution 2.  The 
RNA-coated beads were allowed to air dry, and the RNA was eluted using 50 µl elution 
buffer.  Extracted RNA was transferred to individual 1.5-ml tubes and stored at -20 C.  RNA 
was used for automated sequencing and rRT-PCR assay evaluation.  
Whole matrix gene sequencing and nucleotide analysis.  PCR amplification and 
sequencing primers were designed using 31 APMV-1 nucleotide (nt) sequences from 
GenBank shown in Table 1.  Due to the length of the M gene (approximately 1231 nts), it 
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was divided into four overlapping regions based on the location of conserved sites along the 
gene.  These regions are estimated between the following nucleotides based on NDV B1, 
complete genome (AF309418): region one 3049-3657, region two 3252-3913, region three 
3740-4508, and region four 4356-4662.   
Forward and reverse amplification primers were developed for each region, and 
additional forward and reverse primers were developed to amplify some regions of the class I 
isolates due to nucleotide mismatches in the original primer sites.  Amplicons were 
sequenced using overlapping internal sequencing primers.  Amplification and sequencing 
primer sequences are listed in Table 2.     
Briefly, the Qiagen® One-Step RT-PCR Enzyme Kit was used to prepare the master 
mix and extracted RNA was amplified with a GeneAmp® PCR System 9700 using one 
primer set for each of the four regions.  The following reverse transcription (RT) and 
amplification parameters were used: RT at 50 C for 30 min, reverse transcriptase inactivation 
at 95 C for 15 min, followed by 35 cycles of denaturation at 94 C for 30 sec, annealing at 45 
C for 30 sec and extension at 72 C for 90 sec.  A final 72 C for 10 min allowed for additional 
extension time, followed by an infinite hold at 4 C.  Amplicons were electrophoresed on a 
2% polyacrylamide gel, and resulting bands were visualized using an AlphaImager™ 2200.  
Amplified regions were sequenced on a 3500XL Genetic Analyzer using direct sequencing 
methodologies with multiple overlapping forward and reverse primers.  Each sequenced 
region was analyzed using EditSeq software for incorrect base calls.  All four sequenced 
regions from each isolate were aligned using Sequencher® version 4.9 software, and 
overlapping ends were edited using EditSeq software.  De novo assembly was performed for 
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consensus sequence preparation for the M gene of each isolate.  All partial and full-length M 
gene sequences were uploaded into GenBank and are listed in Table 3.  
 Primer and probe design for diagnostic rRT-PCR.  Consensus sequences from all 
103 isolates were aligned using Sequencher® version 4.9 and manually analyzed to find 
highly conserved sites for primer development.  Primer sites with three or fewer nt 
mismatches were chosen in order to maximize primer binding potential.  A 200-nt maximum 
distance was allowed between primer pairs.  Each primer was evaluated using Integrated 
DNA Technology (IDT®) software for guanine-cytosine (GC) content, secondary structures, 
primer dimers and 3’ end stability (14,19).  Twenty primers were synthesized by IDT® or the 
Iowa State University DNA Facility, and six viruses were tested by each potential primer pair 
using the amplification and visualization method presented previously to evaluate 
amplification efficiency.  All successful primer pairs were further analyzed using additional 
viruses.  The primer pair with the best amplification efficiency was selected and additional 
testing was completed using 119 isolates.  AgPath-IDTM One-Step RT-PCR Kit master mix 
was prepared and the following 7500 Fast Real-Time PCR System protocol was utilized: RT 
at 45 C for 10 min, reverse transcriptase inactivation at 95 C for 10 min, followed by 40 
cycles of denaturation at 94 C for 10 sec, annealing at 45 C for 30 sec and extension at 72 C 
for 10 sec.  Amplicons were evaluated on a 2% agarose gel using the previous method.  
Probe sequences were developed from highly conserved regions positioned between the 
selected primer pair.  Probes were synthesized by Biosearch Technologies, Inc., and rRT-
PCR testing was completed using 43 isolates for each primer-probe set with the previous 
protocol.  Cycle threshold (Ct) values were analyzed to determine the optimal primer-probe 
set.  Table 4 shows the optimal rRT-PCR primer and probe sequences.  Probe M+4097 was 
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designed by removal of all three G nts from the 5’ end of M+4094 (in Table 4) to analyze the 
affect these G’s may have on detection efficiency.  Thirty seven samples were evaluated 
using the original primer set with probe M+4097 (data not shown).    
Assay optimization. Primer and probe concentrations used up to this point, were 
derived from the USDA assay (20).  New primer and probe concentrations were evaluated to 
determine the final concentrations producing the best Ct values.  Recommendations were 
followed from the Applied Biosystems Chemistry Guide, Real-time PCR Current Technology 
and Applications, and personal communication with Dr. Amy Vincent of the Agricultural 
Research Service (19,21).  Three sets of primer and probe concentrations were analyzed 
using three different viruses, LoNDV JN872152, vNDV JN872157 and class I strain 
JN942048, maintaining the rRT-PCR protocol parameters from the previous section.  
 Annealing temperatures were evaluated through IDT® software and rRT-PCR 
analysis.  Annealing temperatures between 30 C and 46 C were analyzed by rRT-PCR 
testing, increasing by increments of two degrees.  All remaining temperatures for the rRT-
PCR protocol remained constant as described in the previous section.  Fluorescence was 
collected at the annealing step.  Several APMV-1 strains representing LoNDV, vNDV, 
cormorant vNDV, PPMV-1, and class I isolates (JN863121, JN872154, JN872152, 
JN872171, JN872191, JN872157, JN872156, JN872187, JN942097, JN942065, JN942057, 
and JN942048) were used in the evaluation.  The Ct values obtained from each annealing 
temperature were compared to the Ct values from the original 45 C annealing temperature. 
 The rRT-PCR assay validation.  Amplification efficiency of the modified and USDA 
assays was evaluated through limit of detection (LOD) testing on four egg infectious dose 
(EID50) titered viruses (class I strain JN942057, vNDV strain JN872157, LoNDV strain 
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JN863120, and PPMV-1 strain JN872166).  Tenfold serial dilutions were prepared from 
extracted viral RNA and tested three times on each assay using the same extracted material.  
LOD was defined as the concentration (expressed as log10 EID50/ml) at which 95% of the 
samples are determined to be positive.  The concentration corresponding to the final dilution 
at which all three replicates of the 10-fold serial dilutions were considered positive was used 
to determine the LOD.  Briefly, RNA was extracted from each titered virus using a 
MagMAXTM-96 Kit and automated KingFisher extraction instrument, and 10-fold serial 
dilutions were performed in RNase free water.  The original extracted RNA and 10-fold 
serial dilutions were tested using the modified and USDA assays.  Three independent dilution 
sequences were performed using the same material on each assay to compare sensitivity.  
Specificity of the modified assay was evaluated using extracted viral RNA from 43 non-
APMV-1 isolates including avian paramyxovirus serotypes 2-4 and 6-9, infectious bronchitis 
virus, infectious bursal disease virus, avian influenza virus H1-H16, avian metapneumovirus, 
avian nephritis virus and avian encephalomyelitis virus.  Isolates were tested using the final 
primer and probe concentrations and optimized annealing temperature.   
Statistical analysis.  Ct values were provided to the Center for Veterinary Biologics 
(CVB) Statistics Section for analysis.  Recommendations from the PCR Assay Validation 
and Methods Comparisons Guidance (unpublished) provided by the NAHLN Methods 
Technical Working Group and the OIE Manual were used to evaluate LOD data (12).  The 
LOD was determined from highest dilution in which all three replicates produced a positive 
Ct value.  Amplification efficiency was estimated as (10[-1/slope])-1 where Ct was regressed on 





M gene sequencing.  M gene sequences in GenBank were limited in length and 
diversity among APMV-1 (downloaded sequences listed in Table 1).  The NVSL repository 
contains a variety of APMV-1 strains, and other foreign laboratories were able to supplement 
the APMV-1 strains used in this study.  The entire M gene was sequenced with the intention 
of providing useful sequences for GenBank and to compare nucleotide sequences for rRT-
PCR primer and probe design.   
The M gene was successfully sequenced for most of the isolates used in the study (see 
Table 3).  The M gene consensus sequence was approximately 1231 nts in length, and the 
coding region was approximately 1094 nts in length for approximately 98% of the isolates.  
Sequencing attempts for two historical isolates, JN942046 and JN942100, were unsuccessful 
after several attempts to sequence region one of the gene.  The M gene consensus sequence 
was limited to the last 1192 nts for JN942046 and only the last 887 nts for JN942100.  
Mismatches between the template RNA and the region one forward primer likely caused the 
lack of amplification from this region.  Both gene sequences had only one mismatch for the 
reverse primer; therefore, it was not believed to have caused the problem.     
Amplification of region two was unable to be completed for six PPMV-1 isolates 
using primers FHF-1, FHF-2, FHR-1, FHR-3 and FHR-4 shown in Table 2.  These isolates 
included JN942090, JN942091, JN942098, JN942095, JN942092 and JN942093.  The 
inability to amplify this region of the six PPMV-1 isolates was caused by mismatches in the 
forward or reverse amplification primers.  All isolates contained two to three mismatches in 
the forward primer binding region and two to four mismatches in the reverse primer binding 
region.  Sequencing for one mesogenic ND isolate JN942094 was limited to regions one, 
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two, and four.  Amplification attempts were ineffective, resulting in the absence of 
approximately 179 nts in region three of the gene sequence.  The forward and reverse primers 
had two to three mismatches in this region, resulting in the lack of primer binding. 
 The rRT-PCR primer design.  The entire M gene was analyzed for rRT-PCR primer 
and probe design.  Evaluation of a variety of primer pairs yielded optimal primer sets located 
at position 4044 and 4239 for forward and reverse primers shown in Table 4.  Forward 
primer at position 4044 was 14 nts in length, and reverse primer at position 4239 was 17 nts 
in length.  Both primers had less than 3 nucleotide mismatches when compared to all 103 
isolates sequenced.  Minimizing the number of primer mismatches was an important design 
feature to optimize the potential for primer binding.   
The rRT-PCR probe design.  Conserved sequences were analyzed first as primers to 
determine template binding ability.  Two short primer sequences were successful during 
primer analysis testing and were subsequently tested as TaqMan™ hydrolysis probes with 
carboxyfluorescein (FAM) fluorescent dye at the 5’ end and a Black Hole Quencher located 
at the 3’ end.  A 17 nucleotide sequence located at position 4094 was selected as the optimal 
probe (Table 4) providing the best Ct values for the 43 isolates tested.  The probe sequence 
M+4094 also contained less than three mismatches, as seen with the forward and reverse 
primers, providing optimum binding potential.   
Results of probe M+4097 evaluation showed a loss of detection for three PPMV-1 
isolates (JN872173, JN942065, and JN942096) and all class I isolates tested (JN942050, 
JN942047, JN942048, JN942049, JN942051, JN942053, JN942055, JN942052, JN942056, 
JN942057, JN942058, and JN942054).  An increase of 6-11 Ct units was also seen for vNDV 
isolates JN942076, JN942086, and JN942087.  This probe was rejected, and additional 
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testing was not performed.  Probe M+4094 was maintained as the selected probe for the 
assay. 
Assay optimization.  Analysis of recommended primer and probe concentration 
resulted in suboptimal results when compared to the original concentrations derived from the 
USDA assay.  Primer final concentrations of 500 nM and probe final concentration of 120 
nM were determined to be the optimal concentrations for amplification.  IDT® software 
evaluation of the primer and template melting temperatures suggested an optimal annealing 
temperature between 35 C and 37 C.  Results of rRT-PCR analysis yielded a wide range of 
differences in Ct values between isolates at each annealing temperature (data not shown).  Ct 
values for the original annealing temperature of 45 C were found to be superior to those 
obtained from the annealing temperature analysis testing.  The annealing temperature of 45 C 
was determined to be optimal for this assay. 
The rRT-PCR assay validation.  Results of LOD testing for the modified and USDA 
assays are shown in Figures 1A,B.  The USDA assay failed to detect class I strain JN942057 
(8.7 log10 EID50/ml undiluted), vNDV strain JN872157 (7.9 log10 EID50/ml undiluted) and 
PPMV-1 strain JN872166 (8.7 log10 EID50/ml undiluted).  The forward primer, reverse 
primer, and probe sequences for the USDA assay had five, four, and six mismatches with 
JN942057, three, two, and two mismatches with JN872157, and two, one, and three 
mismatches with JN872166, respectively.  The modified assay was able to detect all three 
viruses missed by the USDA assay.  The modified assay LOD for JN872166 was calculated 
to be 4.7 log10 EID50/ml.  The modified assay LOD values for JN872157 and JN942057 were 
not calculated due to the lack of a linear relationship between consecutive log10 dilutions for 
each virus.  The amplification efficiency may not be constant for these isolates as indicated 
62 
 
by the lack of linear relationship.  Raw data show consistent detection of JN872157 through 
the 10-2 dilution despite one data point missing in the third replicate due to an aberrant 
fluorescent curve during the rRT-PCR run (data not shown).   
The LOD values for the LoNDV JN863120 were quite variable between the two 
assays.  The USDA assay was able to detect a much lower concentration of JN863120 at 1.63 
log10 EID50/ml, while the modified assay was less sensitive by 3 log10, with an LOD of 4.63 
log10 EID50/ml.  As shown in Figure 1B, the observation corresponding to 2.63 log10 
EID50/ml for the USDA assay did not fall into the linear pattern seen with the remaining 
observations.  This anomaly from the linear pattern may be attributed to inaccurate template 
transfer into the master mix preparation or another type of pipetting error.  Overall results of 
LOD analysis demonstrated enhanced detection capability of the modified assay over the 
USDA assay.  In addition, all 43 non-APMV-1 isolates were not detected using the modified 
assay (data not shown).  This demonstrates a high level of specificity and a lack of cross 
reaction with non-APMV-1 viruses. 
Discussion 
An rRT-PCR developed by Kim et al. (6), targets the L gene of APMV-1 to 
specifically detect class I isolates (5,6,7).  This assay was multiplexed with the current 
USDA matrix assay to allow for detection of a wide range of APMV-1.  Due to extensive 
validation requirements of the USDA, this assay has not been incorporated into the 
diagnostic testing procedures at the NVSL.  The current study was initiated with the intention 
of analyzing the entire M gene to determine if highly conserved regions exist within the gene 
for development of a new rRT-PCR assay that could be used by the NVSL and NAHLN 
laboratories.  Slight modification of the current USDA validated assay would have resulted in 
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minimal validation efforts required to incorporate the assay into the diagnostic testing 
scheme.  An entirely new primer and probe set was developed after sequencing and analysis 
of the M gene for all 103 isolates tested, which will require extensive validation prior to 
acceptance for diagnostic testing.    
 Sequencing primers were designed to provide complete coverage of the M gene.  
Sequence analysis found the M gene to be relatively conserved, but sequence variability 
between strains of APMV-1 was apparent across the entire gene.  Consensus sequences for 9 
of the 103 viruses were limited to partial regions of the M gene after multiple amplification 
attempts.  The lack of nucleotide sequence for these regions was likely due to mismatches 
between the template RNA and the amplification primers.  The vast majority of the isolates 
included in the study were successfully amplified by the chosen primer sets; therefore, 
additional primers were not developed to specifically bind the few regions missed by the 
initial amplification attempts for the nine viruses.  The six PPMV-1 isolates that were unable 
to be amplified in region two of the gene contained two to three mismatches to the forward 
and reverse primers.  The mismatches were not consistent between isolates.  Some had 
multiple mismatches in various locations of the forward primer binding regions.  Others 
appeared to lack amplification due to mismatches in a variety of positions within the reverse 
primer binding regions.  This primer binding problem demonstrates the sequence variability 
among isolates within the PPMV-1 strain of APMV-1.     
Analysis of the primers and probe of the current USDA assay yielded several 
mismatches with many of the isolates used in the study.  This supports the findings of Kim et 
al., who showed that the assay missed many of the class I isolates due to the heterogeneous 
sequences within the M gene (5,6,8).  The presence of multiple mismatches with the current 
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USDA assay led to the goal of minimizing mismatches as much as possible to create the best 
binding potential for the primers and probe in the modified assay.  Test sensitivity has been 
shown to decrease by three to four logs of virus when three to four mismatches are present in 
primers or probes (6,16,22).  These findings are supported by the results of the LOD testing, 
where as few as 3 mismatches in the primer or probe sequences led to a complete loss of 
detection by the USDA assay for JN872157 and JN872166 as shown in Figure 1b.  Manual 
analysis of the sequences for all 103 isolates allowed for minimal mismatches between 
primer/probe binding sites for each of the isolates.  All primer and probe sequences for the 
modified assay contained two or less mismatches to optimize binding potential during rRT-
PCR.  
It is recommended that a G base should not be present at the 5’ end of a fluorogenic 
probe due to the ability of the G base to quench reporter fluorescence even after cleavage of 
the probe (21,23,24).  Probe M+4094 contains three G bases at the 5’ end, contradictory to 
this rule.  Results of rRT-PCR testing where the three G bases at the 5’ end of M+4094 were 
removed to produce probe M+4097 did not support this recommendation.  The assay 
utilizing M+4097 was unable to detect 41% of the isolates tested, and a decrease in 
sensitivity was seen for three vNDV isolates.  These contradictory results emphasize the 
complex nature of probe design.  If all the recommendations for probe design were followed, 
M+4094 would never have been evaluated, and the modified assay would not have been 
produced.   
Primer and probe concentrations used in the current USDA assay were found to have 
the most successful amplification efficiency for the modified assay after various final 
concentrations of the primers and the probe were analyzed.  This may be beneficial if the 
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modified assay is utilized by laboratories currently using the USDA assay.  Reconstitution of 
primers and probe will remain consistent with current procedures.   
Annealing temperature calculations give an estimate of the best temperature based on 
the melting temperature of the less stable primer-template pair (21).  In this instance, both 
primers had similar stability when compared with several templates, so both melting 
temperatures were considered when calculating a range for the annealing temperature.  The 
calculated annealing temperature was not consistent with the actual optimal annealing 
temperature after analysis of a wide range of annealing temperatures.  Template melting 
temperatures likely caused the difference between the calculated annealing temperature and 
the actual optimal annealing temperature.  Genetic variability in the M gene made accurate 
calculation of the annealing temperature difficult.  Real-time RT-PCR cycling parameters for 
the modified assay were based on the current USDA assay.  With the exception of the change 
to a 45ºC annealing temperature, the remainder of the cycling parameters did not change 
from the USDA assay.  Modifications to the cycling parameters programmed in the 
instrument were minimal for adaptation to the modified assay.   
Results of LOD testing showed high variability for the four titered viruses between 
the modified and USDA assays (Fig. 1A and Fig. 1B, respectively).  The modified assay was 
shown to be 3 log10 less sensitive than the USDA assay for JN863120 LOD.  This may 
indicate a reduced ability to detect LoNDV at very low concentrations, which can occur in 
diagnostic specimens.  While this is a concern, we must also take into account that the 
modified assay was designed to detect a broader range of APMV-1, which may lead to a 
decrease in sensitivity for some strains.   
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The lack of detection for the vNDV and PPMV-1 strains by the USDA matrix assay 
is highly concerning.  Both JN872157 and JN872166 originated from sources outside of the 
United States.  Sample JN872157 was isolated from an import case from a quarantine station 
in 2010, and the JN872166 isolate was provided by the IZSV Laboratory in Padova, Italy.  
Infection by either of these viruses in poultry in the United States could have devastating 
consequences.  Rapid detection would be very important in preventing the transmission of 
disease to other flocks.  The inability of the USDA assay to detect these virulent viruses 
could lead to a delayed response to an outbreak, allowing more time for the virus to spread.   
The class I JN942057 was also undetected by the USDA assay during LOD testing.  
Eleven additional class I isolates were tested by the USDA assay and were also found to be 
not detected (data not shown).  These results support the findings by Kim et al., where the 
USDA assay was found to contain several mismatches between the probe and genomic target 
site sequences for several class I viruses (5).  This failure in detection was one of the original 
concerns that led to the interest in developing an rRT-PCR assay that could detect a broader 
range of APMV-1 strains. 
The modified assay was able to detect both virulent strains, JN872157 and JN872166.  
The ability to detect the JN872166 at 4.7 log10 EID50/ml showed a distinct advantage for the 
modified assay over the USDA assay.  Although the LOD may not represent a very low 
concentration of virus, the ability to detect a virus that is missed by another assay proves 
beneficial for diagnostic testing.  Increasing the sensitivity of the modified assay could allow 
for detection of a lower concentration of virus; however, attempts to accomplish this led to a 
reduction in sensitivity for other viruses.  The success of the modified assay to detect a wide 
range of APMV-1 isolates is augmented by its ability to retain a high level of specificity.  
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Lack of detection of all 43 non-APMV-1 viruses demonstrates the assay may be used to 
screen for APMV-1 in species infected with other avian viral diseases without false positive 
results. 
Future studies include extensive validation testing to analyze diagnostic specimens by 
the modified assay.  This evaluation will help determine efficiency of detection when viral 
concentrations are low.  The NVSL and NAHLN laboratories utilize other rRT-PCR 
platforms in addition to the 7500 Fast Real-Time PCR System analyzed in this study.  The 
modified assay may also need to be analyzed using these other platforms to determine 
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Figures and Tables 
Table 1. GenBank Accession Number for M Gene Amplification/Sequencing Primer Design. 
GenBank ID: DescriptionA Gene(s)B VirulenceC 
AB524405 Goose/Alaska/415/91 C Lineage 6 
AB524406 Strain 9a5b C Lineage 6 
AF309418 Newcastle disease virus B1 C LoNDV 
AJ415887 Strain 99299 M PPMV-1 
AJ415888 Strain 99106 M PPMV-1 
AJ415889 Strain 99143 M PPMV-1 
AJ880277 Pigeon paramyxovirus-1 C PPMV-1 
AY140656 Pigeon paramyxovirus-1  M PPMV-1 
AY141208 Pigeon paramyxovirus-1  M PPMV-1 
AY562988 Chicken/U.S.(CA)/1083(Fontana)/72 C vNDV 
AY562991 Chicken/N. Ireland/Ulster/67 C A 
AY626266 Duck/U.S./119535-1/2001  C Lineage 6 
AY626267 Duck/U.S./154979-1/2001  C Lineage 6 
AY626268 Chicken/U.S./101250-2/2001  C Lineage 6 
AY845400 LaSota C LoNDV 
EF026579 Strain 0.025 C PPMV-1 
EF026583 Strain 1.3 C PPMV-1 
FJ410145 PPMV-1/New York/1984 C PPMV-1 
FJ410147 PPMV-1/Maryland/1984 C PPMV-1 
FJ410148 PPMV-1/Texas/1998  C PPMV-1 
GQ288381 Cormorant/US(CA)/D9704285/1997 P Cormorant vNDV 
GQ288382 Cormorant/Canada/98CNN3-V1125/1998 P Cormorant vNDV 
GQ288383 Cormorant/Canada/95DC02150/1995 P Cormorant vNDV 
GQ288384 Cormorant/Canada/95DC2345/1995 P Cormorant vNDV 
GQ288385 Cormorant/US(WI)/18719-03(USGS)/2003 P Cormorant vNDV 
GQ288386 Cormorant/US(NV)/19529-04(USGS)/2005 P Cormorant vNDV 
GQ288387 Cormorant/US(MN)/92-40140/1992 P Cormorant vNDV 
GQ288388 Cormorant/US(CA)/92-23071/1997 P Cormorant vNDV 
GQ429292 Strain AV324/96 C PPMV-1 
GQ429293 Dove/Italy/2736/00 C PPMV-1 
U25835 Texas/GB  M nvNDV 
A Strain description in GenBank. 
B Gene(s): C = complete genome, M = matrix, P = partial genome. 











Table 2. Sequencing and Amplification Primers 






FHF-4 5’-TCAAGCGCCTTGCGCTGAATGG-3’ 3049-3070 1 608 
IR-6 5’-TTAGTTGCACTCTTCTTGCA-3’ 3638-3657 1 608 
IR-13A 5'-GCCAGCTCAACAAG-3' 3596-3609 1  
FHF-1 5’-ATTAAGAAAAAATACGGGT-3’ 3243-3461 2 676 
FHF-2 5’-AAATACGGGTAGAATCGGAG-3’ 3252-3271 2 662 
IF-2A 5’-TGCAAGAAGAGTGCAAC-3’ 3638-3654 2  
IF-9A 5'-ATGCTCTGCCTAGGAAGCGT-3' 3560-3579 2  
L6F-3A 5’-AAAGAGTGCCACGAATACAGAGAGG-3’ 3599-3623 2  
FHR-1 5’-GACATTGAGCGCAAGATTGT-3’ 3894-3913 2 662 
FHR-3 5’-AATAGTGACATTTAGCGC-3’ 3902-3919 2 676 
FHR-4 5’-AATAGTGACATTGAGCGC-3’ 3902-3919 2 676 
SHF-2 5’-GTGAATGCAGTAAAGCACGTGAA-3’ 3740-3762 3 768 
IF-3A 5’-AAGAAAGTGACATTTGACAAG-3’ 4037-4057 3  
IR-12A 5'-GCTGTCCCACTGCTAGAGAA-3' 4169-4188 3  
L6R-3A 5'-GCGGTTCCGCTGCTTGAGAA-3' 4169-4188 3  
SHR-1 5’-CTTCTACCCGTGTTTTTTCTAA-3’ 4487-4508 3 768 
IF-5 5’-TTGCCAAATACAATCCTTT-3’ 4356-4374 4 306 
SHR-3 5'-GCAGCTGCAAGAGGCCTGCC-3 4643-4662 4 306 
IR-14A 5'-AAGAGGCCTGCCATCAA-3' 4638-4654 4  
APrimer used for sequencing only. 


























Table 3. GenBank ID for Uploaded M Gene Sequences  
GenBank ID: DescriptionA Gene(s)B VirulenceC 
JN863120 LaSota M-F LoNDV 
JN863121 New Jersey-Roakin 1946 M-F mNDV 
JN872150 B1 M-F LoNDV 
JN872151 Hitchner M-F LoNDV 
JN872152 Ulster M-F Asymptomatic 
JN872153 Chicken/California/1083(Fontana)/71 M-F vNDV 
JN872154 Beaudette C M-F mNDV 
JN872155 Tennessee 74-2445 M-F NDV 
JN872156 Cormorant Canada M-F Cormorant vNDV 
JN872157 Green Wood Hoope/Eastern 
Hemisphere/5801-22/10 
M-F vNDV 
JN872158 Cormorant/California/24270/97 M-F Cormorant vNDV 
JN872159 Cormorant/Wisconsin/451287-11/06 M-F Cormorant vNDV 
JN872160 Pigeon/Minnesota/511296/07 M-F PPMV-1 
JN872161 Cormorant/Wisconsin/498260-2/07 M-F Cormorant vNDV 
JN872162 Rosella/Belgium/4940/08 M-F vNDV 
JN872163 Chicken/Belize/4224-3/08 M-F vNDV 
JN872164 Chicken/Colombia/440620/06 M-F vNDV 
JN872165 Chicken/Niger/VIR 1377-7/2006 M-F vNDV 
JN872166 Dove/Italy/VIR 24/2008 M-F PPMV-1 
JN872167 Dove/FL/455682-2/2006 M-F PPMV-1 
JN872168 Chicken/Dominican Republic/499-31/2008 M-F vNDV 
JN872169 Pennsylvania/3167/2009 M-F LoNDV 
JN872170 Pigeon/Texas/5254-12/2010 M-F PPMV-1 
JN872171 Turkey/Minnesota/17531-3/2010 M-F LoNDV 
JN872172 Raptor/Minnesota/18575-4/2009 M-F PPMV-1 
JN872173 Pigeon/New York/44407/1984 M-F PPMV-1 
JN872174 New Jersey/9564/2010 M-F PPMV-1 
JN872175 Pigeon/Minnesota/723/2009 M-F PPMV-1 
JN872176 Pheasant/Massachusetts/359425/2005 M-F PPMV-1 
JN872177 Chicken/Massachusetts/344783-3/2004 M-F PPMV-1 
JN872178 Turkey/Louisiana/331309/2004 M-F PPMV-1 
JN872179 Pigeon/Nevada/241851/2003 M-F PPMV-1 
JN872180 Waterfowl/Texas/209682/2002 M-F PPMV-1 
JN872181 Chicken/Honduras/44813/2000 M-F vvNDV 
JN872182 Pigeon/New York/12339/1998 M-F PPMV-1 
JN872183 Pigeon/Maryland/2075/1998 M-F PPMV-1 
JN872184 Pigeon/Wyoming/20210/1997 M-F PPMV-1 
JN872185 Pigeon/New York/32851-2/1995 M-F PPMV-1 
JN872186 Pigeon/Indiana/18002/1991 M-F PPMV-1 
JN872187 Pigeon/Illinois/11748/1993 M-F PPMV-1 
JN872188 Pigeon/Minnesota/2446/1989 M-F PPMV-1 
JN872189 Parrot/Colorado/8278/1982 M-F vvNDV 
JN872190 Pigeon/South Dakota/486839/2007 M-F PPMV-1 
JN872191 Chicken/Texas (GB)/1948 M-F nvNDV 
JN872192 Chicken/California/211472-4/2002 M-F vNDV 
JN872193 Avian/Peru/1918-3/2008 M-F vNDV 
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Table 3. Continued. 
GenBank ID: DescriptionA Gene(s)B VirulenceC 
JN872194 Chicken/Honduras/498109-15/2007 M-F vNDV 
JN942046 Tokyo M NDV 
JN942047 New Jersey/13890-2/2010 M Lineage 6 
JN942048 Muscovy Duck/Pennsylvania/10145/2010 M Lineage 6 
JN942049 New Jersey/32796-2/2009 M Lineage 6 
JN942050 Duck/Pennsylvania/33250/2009 M Lineage 6 
JN942051 Poultry/Florida/31670-4/2009 M Lineage 6 
JN942052 Mallard/Connecticut/17847-2/2009 M Lineage 6 
JN942053 Northern Pintail/Michigan/28171-16/2009 M Lineage 6 
JN942054 Raptor/Minnesota/18575-1/2009 M Lineage 6 
JN942055 Mallard/Wisconsin/22853/2009 M Lineage 6 
JN942056 Mallard/Oregon/13685/2009 M Lineage 6 
JN942057 Wood Duck/Louisiana/2193/2008 M Lineage 6 
JN942058 Mallard/Ohio/2080-2/2008 M Lineage 6 
JN942059 Chicken/Colombia/118-05/2008 M vNDV 
JN942060 Chicken/Colombia/3084-23/2008 M LoNDV 
JN942061 Cormorant/Chile/9138/2007 M vNDV 
JN942062 Avian/Peru/3442-6/2009 M LoNDV 
JN942063 Cormorant/Oregon/399448/2005 M Cormorant vNDV 
JN942064 Cormorant/Nevada/395921/2005 M Cormorant vNDV 
JN942065 Chicken/Texas/309968/2004 M PPMV-1 
JN942066 Cormorant/Oregon/276236-7/2003 M Cormorant vNDV 
JN942067 Cormorant/Wisconsin/272409/2003 M Cormorant vNDV 
JN942068 Cormorant/New York/269385/2003 M Cormorant vNDV 
JN942069 Cormorant/New York/268898-7/2003 M Cormorant vNDV 
JN942070 Fighting Cock/Nicaragua/95066-9/2001 M vvNDV 
JN942071 Chicken/Mexico/51735-8/2000 M vvNDV 
JN942072 Cormorant/Wisconsin/248/1998 M Cormorant vNDV 
JN942073 Cormorant/Wisconsin/28547/1997 M Cormorant vNDV 
JN942074 Chicken/Mexico/37821-2/1996 M vvNDV 
JN942075 Amazon/Missouri/31378/1996 M vvNDV 
JN942076 Avian/Chile/37646/1996 M nvNDV 
JN942077 Ostrich/South America/45445-3/1995 M nNDV 
JN942078 Cormorant/North Dakota/43888-6/1992 M Cormorant vNDV 
JN942079 Turkey/North Dakota/43084-25/1992 M Cormorant vNDV 
JN942080 Cormorant/Minnesota/40140/1992 M Cormorant vNDV 
JN942081 Cormorant/Michigan/38819-5/1992 M Cormorant vNDV 
JN942082 Amazon/California/28936/1988 M vvNDV 
JN942083 Parrot/New Jersey/19674-2/1986 M vvNDV 
JN942084 Cockatoo/Oklahoma/7847/1983 M vvNDV 
JN942085 Amazon/California/16365/1981 M vvNDV 
JN942086 Roller/Tanzania/47385-11/2010 M vNDV 
JN942087 Roller/Tanzania/47387-6/2010 M vNDV 
JN942088 Turkey/Belize/4438-4/2008 M vNDV 
JN942089 Pigeon/California/2293/2008 M PPMV-1 
JN942090 Pigeon/California/7236/2009 M PPMV-1 
JN942091 Pigeon/New Jersey/58300-4/2000 M PPMV-1 
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Table 3. Continued. 
GenBank ID: DescriptionA Gene(s)B VirulenceC 
JN942092 Pigeon/Illinois/37397/1987 M PPMV-1 
JN942093 Pigeon/Maryland/11936/1985 M PPMV-1 
JN942094 Psittacine/Indiana/29120/1980 M mNDV 
JN942095 Pigeon/Oklahoma/7668/1997 M-F PPMV-1 
JN942096 Duck/Louisiana/36166-35GW/1988 M-F LoNDV 
JN942097 Cormorant/Wisconsin/1926/2008 M-F Cormorant vNDV 
JN942098 Pigeon/North Carolina/56404/2000 M-F PPMV-1 
JN942099 Gannet/Pennsylvania/25017/2000 M-F PPMV-1 
JN942100 Chukar/New Jersey/32429-5/2000 M-F PPMV-1 
JN942101 Finch/Eastern Hemisphere/1409-12/2008 M-F vNDV 
AStrain description in GenBank. 
BGene(s):  M = matrix, M-F = matrix-fusion. 
CLo = low-virulence, M = mesogenic, VV = viscerotropic velogenic, NV = neurotropic velogenic,  


















Table 4. rRT-PCR Primers and Probe. 
Primer Sequence 5’→3’ PositionA (bp) Amplicon size (bp) 
M+4044 5’-TGACATTTGACAAG-3’ 4044-4057 196 
M-4239 5’-CTCCAGAGTATCTTAGC-3’ 4223-4239 196 
M+4094 5'-d FAM-GGGCTCAGTGATGTGCT-BHQ-3' 4094-4110  







Figure 1. Limit of Detection Using Modified and USDA assays. 
 
   A. 
 
                            B. 
 
Fig. 1. Limit of detection using modified and USDA assays.  Cycle threshold values plotted against consecutive EID50/ml 
log10 dilutions.  Data points for isolates JN942057, JN872157, JN872166, and JN63120 are slope estimates from linear 
regression models.  Black, green and blue lines represent each of three replicates of 10-fold serial dilutions for each isolate.  
(A) Cycle threshold data points obtained from a log10 dilution series of each isolate using the modified assay. (B) Cycle 
threshold data points obtained from a log10 dilution series of isolate JN863120 using the USDA assay.  Data points are not 
shown for isolates JN942057, JN872157, and JN872166 due to a lack of detection by the USDA assay. 
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CHAPTER 4.  ANALYSIS OF THE AVIAN PARAMYXOVIRUS SEROTYPE-1 
FUSION GENE FOR PIGEON PARAMYXOVIRUS-1 AND CORMORANT 
VIRULENT NEWCASTLE DISEASE RRT-PCR PRIMER DEVELOPMENT 
 
Abstract 
The fusion (F) gene of avian paramyxovirus serotype-1 (APMV-1) is the target of the 
current United States Department of Agriculture validated real-time reverse-transcription 
polymerase chain reaction (rRT-PCR) assay designed to detect virulent strains of Newcastle 
disease (vND) virus.  This assay is an important diagnostic tool used in laboratories across 
the United States to obtain diagnostic results in a short time period.  Some virulent strains of 
APMV-1, including pigeon paramyxovirus-1 and the strain of vND infecting cormorants, are 
not consistently detected by the current F gene assay.  The limited detection capability of the 
current assay may result in delayed diagnosis of vND.  We sequenced the full F gene of 118 
APMV-1 isolates to supplement the limited amount of nucleotide sequences available in 
GenBank and attempted to design primers for a new rRT-PCR assay to specifically detect all 
strains of pigeon paramyxovirus-1 and cormorant vND.  Conventional RT-PCR analysis 
demonstrates that, due to the relatively conserved F gene sequence composition of APMV-1, 
primer sequences could not be identified to exclusively bind the target strains.  Due to the 
conserved nature of the F gene, a target specific primer and probe set could not be produced 
for the development of a new rRT-PCR assay. 
Introduction  
 Avian paramyxovirus serotype-1 (APMV-1) is a negative sense, single-stranded, non-
segmented, enveloped virus commonly referred to as Newcastle disease virus (NDV) (1,2,3).  
It is a member of the order Mononegavirales, family Paramyxoviridae, and genus 
Avulavirus.  The genome encodes six proteins including; the nucleocapsid (NP), 
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phosphoprotein (P), matrix (M), fusion (F), hemagglutinin-neuraminidase (HN) and the 
RNA-dependent RNA polymerase (L).  Presence of multiple basic amino acids at the F 
protein cleavage site allows virulent strains of NDV (vNDV) to replicate systemically.  
APMV-1 includes a variety of virulent and low-virulence viruses.  The majority of field 
isolates in the U.S. are low-virulence vaccine-like viruses, as live attenuated viruses are used 
routinely for vaccination, but vNDV periodically causes clinical disease in double-crested 
cormorants in the U.S. (4,5).  Although adult cormorants are considered to be the natural 
reservoir for this strain of NDV, the disease causes high morbidity and mortality in juvenile 
cormorants.  The virus is detected in the U.S. during the time when juveniles leave their nests 
and begin to migrate.  The virus has been detected sporadically with the most recent 
detections occurring in 2008 and 2010 (6).  This strain of vNDV is usually restricted to 
cormorants, but in 1992 the virus was transmitted to non-confined turkeys in North Dakota 
(1).  Because this strain has shown the ability to infect poultry, the disease remains a 
potential problem for the poultry industry.  
  Pigeons are the natural reservoir for another species-adapted strain of APMV-1, 
pigeon paramyxovirus-1 (PPMV-1) (7,8).  This virus is more virulent in pigeons, but all 
members of the order Columbiformes are considered susceptible (5,7,8,9).  Some strains may 
cause neurologic signs in chickens and pigeons (5,8).  Results of chicken pathogenicity 
testing demonstrate a lack of significant respiratory signs and only intermediate virulence in 
chickens (5,8).  The virus was shown to have the ability to adapt to poultry causing an 
outbreak in chickens in Great Britain in 1984 (7,8).  Fecal contamination of food led to 23 
outbreaks in commercial chickens (1,7).  PPMV-1 has not naturally infected chickens in the 
U.S., but both cormorant vNDV and PPMV-1 have been shown to replicate in poultry 
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(5,7,8,9).  Either virus could potentially cause large economic losses to the agricultural 
industry.  Both strains of APMV-1 are classified as virulent according to the guidelines 
established by the World Organization for Animal Health (OIE) (7,10).  
  Virus isolation (VI) and real-time reverse-transcription PCR (rRT-PCR) are the two 
major tools used in APMV-1 diagnostic testing at the National Veterinary Services 
Laboratories (NVSL).  VI is the “Gold Standard” and is used to confirm rRT-PCR results.  
Isolation can take 5 to 10 days, and additional time is required to characterize the virus.  
Classical methods of identifying the virus in harvested allantoic fluid include the 
hemagglutination (HA) and hemagglutination-inhibition (HI) assays, which are limited by 
the poor hemagglutinating ability of cormorant vNDV (9,10).  There is the potential for false 
negative results with the HA assay which is a significant concern if the isolate originates 
from a poultry specimen.  The NVSL and National Animal Health Laboratory Network 
(NAHLN) utilize an rRT-PCR screening assay designed to detect the M gene of APMV-1 
and a pathotyping assay specific for the F gene of vNDV (11,12,13).  The ability to rapidly 
pathotype these strains using rRT-PCR allows for a quick detection and response to an 
outbreak and can greatly reduce economic loss.   
The current USDA validated F gene rRT-PCR assay fails to detect many cormorant 
vNDV isolates (4).  As indicated by a recent publication and supported by diagnostic testing 
at the NVSL, some PPMV-1 strains are also not detected by the F gene assay (14).  
Mismatches in the probe binding site for some strains of PPMV-1, result in a loss of binding 
and failure in detection.  The inability to detect virulent strains of APMV-1 is a problem 
because of the potential for introduction into poultry.  The objectives of this study were to 
sequence the F gene of APMV-1 isolates and evaluate the potential for development of a new 
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F gene assay able to specifically detect only the cormorant vNDV and PPMV-1 strains of 
APMV-1.  The assay design method included primer design and analysis by conventional 
RT-PCR, followed by design of a TaqMan™ hydrolysis probe located between primer sites, 
and finally primer and probe evaluation by rRT-PCR.  F gene sequence analysis and primer 
design are described.  
Materials & Methods 
 Isolates and RNA extraction.  RNA was extracted from 118 APMV-1 isolates 
originating from wild birds and poultry isolated between 1980 and 2010 and from historical 
reference viruses from the NVSL APMV-1 virus repository.  Two isolates were received 
from the Istituto Zooprofilattico Sperimentale delle Venezie in Padova, Italy, 31 isolates 
were acquired from the Instituto Colombiano Agropecuario (ICA) Laboratory in Bogota, 
Colombia (four isolates were used for F gene sequencing), and two isolates were received 
from the Servicio Agrícola y Ganadero (SAG) in Santiago, Chile (one isolate was used for F 
gene sequencing).  Isolates are listed in Table 3.  Of the 118 isolates, 8 were pathotyped as 
low-virulence NDV (LoNDV), 37 as vNDV, 23 additional vND viruses were isolated from 
cormorants, 37 were pigeon paramyxovirus type-1 (PPMV-1), and 13 low-virulence isolates 
were characterized as class I APMV-1.  The class I classification method is based on the 
genomic characterization and sequence analysis of the F and L genes (15,16).  RNA was 
extracted using a commercial extraction kita and automated extraction instrumentsb.  Briefly, 
50 µl of each isolate was added to 100 µl Viral Lysis/Binding Solution and 20 µl Bead 
Resuspension Mix.  Extracted RNA was washed once in Wash Solution 1 and twice in Wash 
Solution 2.  The RNA coated beads were allowed to air dry, then the RNA was eluted using 
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50 µl Elution Buffer.  Extracted RNA was transferred to individual 1.5 ml tubes and stored at 
-20ºC.  RNA was used for automated sequencing and rRT-PCR primer evaluation.  
 Fusion gene sequencing and nucleotide analysis.  Sequencing primers for F gene 
amplification were designed using 40 APMV-1 nucleotide sequences of GenBank isolates 
listed in Table 1.  For sequencing purposes, the gene was divided into three overlapping 
regions.  These regions are estimated based on NDV B1, complete genomic nucleotide 
sequence (AF309418); region one 4487-5385, region two 5081-5771, and region three 5602-
6335.  Due to genetic diversity, additional reverse primers were developed to amplify regions 
one and two of the class I isolates.  Primer sequences are listed in Table 2. 
Briefly, master mixc was prepared, and extracted RNA was amplifiedd using one 
primer set for each of the three regions.  The following reverse transcription and 
amplification parameters were used: reverse transcription at 50ºC for 30 minutes (min), 
reverse transcriptase inactivation at 95ºC for 15 min, followed by 35 cycles of denaturation at 
94ºC for 30 seconds (sec), annealing at 45ºC for 30 sec and extension at 72ºC for 1:30 min.  
A final 72ºC for 10 min allowed for additional extension time followed by an infinite hold at 
4ºC.  Amplicons were electrophoresed on a 2% polyacrylamide gel, and resulting bands were 
visualizede.  Gel extraction was performedf to excise the appropriate band when amplification 
resulted in multiple bands.  Direct sequencingg methodologies were used to obtain three 
passes for each region using either two sets of forward primers and one reverse primer or 
vice versa.  Base readsh were corrected and de novo assembly was performed for consensus 
sequence preparation.  All full-length and partial F gene sequences were uploaded into 
GenBank and are listed in Table 3.  
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 The rRT-PCR primer design.  Consensus sequences from all 118 isolates were 
alignedi, and the F gene was manually analyzed base-by-base to locate conserved sites along 
the gene.  Primer design methodology was to first identify primers with the highest degree of 
similarity to the consensus sequences of the cormorant vNDV and PPMV-1 target strains 
then eliminate primers that were not unique to these target strains.  Only primer sites with 
less than three mismatches to the target strains were analyzed in order to maximize primer 
binding potential.  Primers with at least three or more mismatches with all other non-target 
APMV-1 isolates were selected for further analysis.  A 200 nucleotide distance is optimal 
between primer pairs for rRT-PCR but, due to the lack of conserved sequences in the 
cormorant vNDV and PPMV-1 target strains, some analyzed primer pairs were separated by 
more than 200 nts.   
Thirteen primers were evaluatedj for GC content, secondary structures, primer dimers 
and 3’ end stability prior to synthesisj (first 13 primers listed in Table 4) (17).  Nine viruses 
(LoNDV isolates GenBank ID: JN863120 and GenBank ID: JN872150, mesogenic NDV 
(mNDV) strain GenBank ID: JN863121, PPMV-1 strains GenBank ID: JN872167 and 
GenBank ID: JN872177, neurotropic velogenic NDV (nvNDV) strain GenBank ID: 
JN872191, and cormorant vNDV strains GenBank ID: JN942036, GenBank ID: JN942021, 
and GenBank ID: JN942024) were tested by each potential primer pair using the 
amplification and visualization method above to evaluate amplification efficiency for various 
strains of APMV-1 (gel images in Figure 1).  The forward and reverse primers were 
redesigned to reduce non-target strain binding.  Additional mismatches directed at non-target 
strains were introduced into the previous primer sequences (primer sequences not shown).  
Alignment of redesigned primers indicated the inserted mismatches were not specific to non-
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target APMV-1 strains, and mismatches were also seen with the cormorant vNDV and 
PPMV-1 target strains.  These primers were not analyzed by PCR amplification due to the 
potential for reduced amplification of the target strains when more than three mismatches 
were present in the primer sequences.  A second attempt to decrease non-target strain binding 
was performed by destabilizing the 3’ or 5’ primer ends through the addition of less stable 
adenine or thymine bases where available.  Thirteen redesigned primers were synthesizedj 
(last 13 primers listed in Table 4).  Destabilized primers were analyzed using the same set of 
nine viruses tested with the original primer sets.   
Results 
F gene sequencing.  Complete F gene sequence data was obtained for 95% of the 
isolates using the primers designed for the sequencing portion of the project.  The primers 
failed to amplify the 5’ end of the gene for 43% of the isolates resulting in the lack of a small 
portion of variable length at this end of the gene.  A new forward primer (M4094) developed 
in a previous study (Hines et al., 2012), was used for the remaining isolates which bound the 
RNA near the end of the M gene (18).  Mismatches between the template RNA of historical 
isolate GenBank ID: JN942003, LoNDV strain GenBank ID: JN942017 and vNDV strains 
GenBank ID: JN94198, GenBank ID: JN942016, and GenBank ID: JN942018 and the 
forward and/or reverse amplification primers led to a lack of amplification for region one.   
Primer mismatches also prevented amplification for class I strain GenBank ID: 
JN942014 in region three.  The chosen primer sets for region three resulted in successful 
sequencing for the remainder of the isolates in the study so additional primers were not 
developed to specifically amplify this isolate.  This primer binding problem demonstrates the 
sequence variability among class I isolates.  The F gene consensus sequence was 
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approximately 1781 nucleotide for the majority of the isolates and the coding region was 
approximately 1661 nucleotides in length.  The F gene was found to contain some relatively 
conserved regions interspersed among vast stretches of heterologous sequence.  
The rRT-PCR primer analysis. As shown in Figure 1, primer pair F+4634/F-4795 
showed good amplification of all five target strains tested (GenBank ID: JN872167, 
GenBank ID: JN942036, GenBank ID: JN942021, GenBank ID: JN872177, and GenBank 
ID: JN942024).  Reduced amplification was seen for LoNDV strains GenBank ID: JN863120 
and GenBank ID: JN872150 and amplification of mNDV strain GenBank ID: JN863121 was 
extremely weak.  Primer pairs F+4731/F-4927 showed good amplification for all strains 
except non-target vNDV strain GenBank ID: JN872191.  Primer pairs F+4778/F-4927, 
F+5291/F-5646 and F+5625/F-5725 showed good amplification for all nine strains of 
APMV-1.  Good amplification of the target strains were seen with primer pairs F+4904/F-
5240 and F+5222/F-5314.  These primers showed no detection of LoNDV or mNDV strains 
but maintained efficient amplification for the non-target vNDV (GenBank ID: JN872191).  
Figure 2 shows results from destabilized primer testing (last 13 primers in Table 4).  
Primer pair F+4731d/F-4797d had weak bands for target strains GenBank ID: JN942036, 
GenBank ID: JN942021, GenBank ID: JN872177, and GenBank ID: JN942024, therefore, 
sensitivity of that primer pair was low.  Amplification of all strains except mNDV GenBank 
ID: JN863121 was seen with primer pair F+4731d/F-4924d .  Amplification of all APMV-1 
strains was seen with primer pairs F+4778d/F-4924d, F+5291d/F-5651d, and F+5627d/F-
5727d.  Primer pair F+5221d/F-5315d was also able to amplify all strains except target strain 
GenBank ID: JN942024. 
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Primer pairs F+4634 (original)/F-4749d and F+4904d/F-5241d resulted in no 
amplification for LoNDV GenBank ID: JN863120 and GenBank ID: JN872150 and mNDV 
GenBank ID: JN863121, good amplification for target strains GenBank ID: JN872167, 
GenBank ID: JN942036, GenBank ID: JN942021, GenBank ID: JN872177, and GenBank 
ID: JN942024 and reduced amplification for non-target vNDV strain GenBank ID: 
JN872191.  Additional testing was conducted for these primer pairs plus primer pair F+4634 
(original)/F-4924d using 12 viruses not previously tested (GenBank ID: JN872152, GenBank 
ID: JN872190, GenBank ID: JN872153, GenBank ID: JN872154, GenBank ID: JN872157, 
GenBank ID: JN872192, GenBank ID: JN942097, GenBank ID: JN872193, GenBank ID: 
JN872173, GenBank ID: JN872172, GenBank ID: JN942011, and GenBank ID: JN941988) 
(gel images shown in Figure 3).  Primer pair F+4634 (original)/F-4749d was shown to have 
inconsistent amplification of PPMV-1.  Pigeon paramyxovirus-1strains GenBank ID: 
JN872173 and GenBank ID: JN872172 showed good amplification while GenBank ID: 
JN872190 had an extremely weak band on the gel in Figure 3.  Primer pairs F+4634 
(original)/F-4924d amplified all non-target APMV-1 strains except for class I isolate 
GenBank ID: JN942011 and vNDV GenBank ID: JN872157.  Finally primer pair 
F+4904d/F-5241d amplified all non-target APMV-1 strains except mNDV GenBank ID: 
JN872154 and class I isolate GenBank ID: JN942011.  No primer pairs were shown to detect 
only the cormorant vNDV and PPMV-1 strains of APMV-1.   
Discussion 
The inability of the current USDA validated F gene rRT-PCR assay to detect many 
PPMV-1 and cormorant vNDV isolates led to the interest in developing a separate assay that 
can specifically detect these strains of APMV-1 circulating in North America (4,9,14,15).  
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Mismatches in the probe binding site have been shown to be more difficult to overcome than 
primer mismatches (17).  Redesign of the current probe would address the lack of detection 
while still using the same primer set.  A slight modification such as this would have resulted 
in minimal validation efforts to incorporate the assay into the diagnostic testing scheme.  
Sequence variability of the F gene makes probe redesign a challenge.  Addition of a second 
probe to the assay is also an option but may lead to a loss in sensitivity due to competition for 
binding sites.  Due to these challenges, the current study was initiated with the intention of 
analyzing the full F gene to determine if conserved regions exist for development of a new 
set of primers and probe that could detect only the cormorant vNDV and PPMV-1 strains.  If 
successful, this assay would be used to supplement the current USDA validated assay 
without having to make changes to the original assay.   
GenBank contained a limited variety of APMV-1 F gene sequences, and the length of 
available sequences was insufficient for the purposes of this study.  Strains from the NVSL 
repository and isolates received from foreign laboratories were used to obtain the large 
variety of APMV-1 strains required for this study.  The entire F gene was sequenced for two 
purposes.  The first purpose was to compare nucleotide sequences across the gene from a 
wide range of APMV-1 for rRT-PCR assay development.  The second purpose was to 
perform nucleotide sequencing on 118 temporally and spatially diverse APMV-1 isolates in 
order to increase the amount of F gene sequence data available in the GenBank database. 
Real-time RT-PCR sensitivity has been shown to decrease by three to four logs of 
virus when three to four mismatches are present in primers or probes (14,16,19).  The goal of 
this study was to design primers with more than three mismatches to non-target sequences to 
reduce non-target strain primer binding.  Despite multiple non-target strain mismatches, all 
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primer pairs evaluated by RT-PCR yielded unwanted amplification of non-target strains.  
Primer pairs F+4904/F-5240 and F+5222/F-5314 showed some potential due to their ability 
to bind all target strains with reduced non-target strain binding.  None of the original seven 
primer pairs were able to selectively bind only the cormorant vNDV and PPMV-1 target 
strains.   
It is well known that the additional hydrogen bond within guanine-cytosine (G-C) 
base pairings provides stronger bond strength than in thymine-adenine (A-T) base pairings 
(20,21).  Since the primers contained multiple mismatches with non-target isolates, it was 
theorized that weakening the primer binding at the vulnerable 3’ or 5’ ends of the primers 
may reduce non-target amplification.  Addition of multiple sequence specific thymine or 
adenine bases at the either end of each primer was performed in an attempt to destabilize the 
primer binding for the non-target isolates.  This destabilization attempt resulted in decreased 
target strain amplification, lack of a significant decrease in non-target strain binding, and 
sometimes inconsistent amplification of the target strains.  The destabilization theory was 
proven to be an ineffective technique for enhancing target-specific primer binding.  
The current USDA validated F gene assay has been very effective at detecting most 
North American strains of virulent NDV.  The original goal in developing an assay specific 
for cormorant vNDV and PPMV-1 was to gain the ability to differentiate these strains from 
other vNDV detected by the current USDA F gene assay.  Future studies could include 
additional sequence analysis to determine if multiple rRT-PCR assays could be developed 
specific to each strain of vNDV.  The cormorant vNDV sequences could be analyzed to 
develop an rRT-PCR specific for that strain while the PPMV-1 sequences are analyzed 
separately for development of a second assay.  This option may lend the ability to distinguish 
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between virulent strains based on assay specific detection.  If successful, this method would 
require diagnostic laboratories to incorporate multiple assays into their routine diagnostic 
testing.  Additional sample processing, increased technical labor, and reagent costs are major 
disadvantages therefor this method was not considered in this study.  
A second option for future study is designing degenerate primers.   Differences in the 
nucleotide sequence across the F gene reduce the primer target regions to areas that are more 
conserved across all strains of APMV-1.  This limits the ability to exclude low-virulence 
strains from primer binding.  Degenerate primers may lend the opportunity to target less 
conserved regions that contain sequence variability between virulent and low-virulence 
strains.  This may lead to development of an assay that completely excludes all low-virulence 
strains due to lack of primer recognition.  Finally, a study could be done to determine if 
regions exist for development of primers and probes to detect all strains of virulent NDV, 
including cormorant vNDV and PPMV-1.  Development of a single assay capable of 
detecting all strains of vNDV would benefit diagnostic testing despite the inability to 
distinguish between virulent strains.   
As previously mentioned, conserved regions unique only to the target strains were not 
present in the F gene.  Limited sequence homology was observed across the entire gene for 
the PPMV-1 isolates.  Very few conserved regions existed within this strain for primer 
sequence design.  The majority of these few conserved regions were also found to be 
conserved in other strains of APMV-1.  This finding limits the ability to produce degenerate 
primers that could exclusively bind PPMV-1 strains and also reduces the probability that 
primers could be designed to detect all vNDV including PPMV-1 while excluding low-
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virulence strains.  For this reason, it is unlikely that any of the three options for future studies 
would be successful using the F gene for rRT-PCR primer design. 
Conclusions 
The objective of the study was to identify conserved regions unique to cormorant 
vND and PPM-1 viruses.  Conserved regions unique only to the target strains were unable to 
be located using manual base-by-base comparison of the entire F gene.  The conserved 
regions of these viruses were remarkably similar to other APMV-1 non-target viruses.  
Alignment and RT-PCR analysis conclude that a single primer pair will not exclusively 
amplify only the cormorant vNDV and PPMV-1 target strains without at least some 
amplification of other non-target strains.  Probe design for rRT-PCR assay development was 
not attempted due to the inability to produce primers specific to the target strains.        
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Tables and Figures 
Table 1. GenBank ID for F Gene Amplification/Sequencing Primer Design 
GenBank ID: * Description † Gene(s) ‡ Virulence 
AF217084 Newcastle disease virus  F LoNDV 
AB524405 Goose/Alaska/415/91 C Lineage 6 
AB524406 Strain 9a5b C Lineage 6 
AF309418 Newcastle disease virus B1 C LoNDV 
AJ880277 Pigeon paramyxovirus-1 C PPMV-1 
AY289000 Chicken/USA/Roakin/48  F mNDV 
AY562988 Chicken/U.S.(CA)/1083(Fontana)/72 C vNDV 
AY562991 Chicken/N. Ireland/Ulster/67 C A 
AY626266 Duck/U.S./119535-1/2001  C Lineage 6 
AY626267 Duck/U.S./154979-1/2001  C Lineage 6 
AY626268 Chicken/U.S./101250-2/2001  C Lineage 6 
AY734535 Pigeon/Argentina/Tigre 6/99  F PPMV-1 
AY734536 Pigeon/Argentina/Capital 3/97  F PPMV-1 
AY845400 LaSota C LoNDV 
AY972103 Duck/FarEast/2687/2001  F APMV-1 
EF026579 Strain 0.025 C PPMV-1 
EF026583 Strain 1.3 C PPMV-1 
EU477189 Pigeon/US/RI166/2000  F PPMV-1 
EU477190 Pigeon/US/TX3503/2004  F PPMV-1 
EU477191 Eurasian collared dove/US/TX3988/2004  F PPMV-1 
EU477192 Eurasian collared dove/US/TX4156/2005  F PPMV-1 
FJ410145 PPMV-1/New York/1984 C PPMV-1 
FJ410148 PPMV-1/Texas/1998  C PPMV-1 
FJ865434 Pigeon paramyxovirus-1 strain s-1  F PPMV-1 
FJ986192 2K3/Chennai/Tamil Nadu C PPMV-1 
GU332655 Cormorant/US/496/2008 F Cormorant vNDV 
GU332657 Cormorant/US/498/2008  F Cormorant vNDV 
GU332662 Cormorant/US/503/2008  F Cormorant vNDV 
GU332663 Cormorant/US/506/2006  F Cormorant vNDV 
GQ288381 Cormorant/US(CA)/D9704285/1997 P Cormorant vNDV 
GQ288382 Cormorant/Canada/98CNN3-V1125/1998 P Cormorant vNDV 
GQ288383 Cormorant/Canada/95DC02150/1995 P Cormorant vNDV 
GQ288384 Cormorant/Canada/95DC2345/1995 P Cormorant vNDV 
GQ288385 Cormorant/US(WI)/18719-03(USGS)/2003 P Cormorant vNDV 
GQ288386 Cormorant/US(NV)/19529-04(USGS)/2005 P Cormorant vNDV 
GQ288387 Cormorant/US(MN)/92-40140/1992 P Cormorant vNDV 
GQ288388 Cormorant/US(CA)/92-23071/1997 P Cormorant vNDV 
GQ429292 Strain AV324/96 C PPMV-1 
GQ429293 Dove/Italy/2736/00 C PPMV-1 
X04719 Newcastle disease virus F mNDV 
* Strain description in GenBank 
† Gene(s) F=fusion, C=complete genome, P=partial genome 
‡ Lo=Low-virulence, Lineage 6=Class I, PPMV-1=Pigeon paramyxovirus-1, M=Mesogenic, V=Virulent, A=Asymptomatic  
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 Table 2. Sequencing and Amplification Primers 
Primer Sequence 5’→3’ ‡ Position 
(bp) 
Primer Pair Amplicon 
size (bp) 
M4094 5’-GGGCTCAGTGATGTGCT-3’ 4094-4110 M4094/F5304r 1210 
F4487f 5’-TTAGAAAAAACACGGGTAGAAG-3’ 4487-4508 F4487f/F5322r 835 
*F5245r 5’-GGTCAACTGCGTGAGTGC-3’ 5228-5245 F4487f/F5245r 758 
F5304r 5’-GTCAACAAGTAATCCATATTGC-3’ 5283-5304 M4094/F5304r 1210 
F5322r 5’-TTCCCTACACCTAACTT-3’ 5306-5322 F4487f/F5322r 835 
F5385r 5’-TGAGTCTGTGAGTCATA-3’ 5369-5385 F4487f/F5385r 898 
F5081f 5’-GGGAAGATGCAGCAGTTTG-3’ 5081-5100 F5081f/F5771r 690 
*F5698r 5’-TGTCATATATGGTGTGGTG-3’ 5680-5698 F5081f/F5698r 617 
F5771r 5’-GCGATATGATACCTGGGG-3’ 5754-5771 F5081f/F5771r 690 
F5602f 5’-CCCCATGTCTCCTGG-3’ 5602-5616 F5602f/F6335r 733 
†F5631f 5’-TGAGCGGCAATACATC-3’ 5631-5646 F5631f/F6331r 700 
†F6331r 5’-GTTCTACCCGTGTAT-3’ 6317-6331 F5631f/F6331r 700 
F6335r 5’-GACCGTTCTACCCGT-3’ 6321-6335 F5602f/F6335r 733 
* Primer used for Class I viruses only 
†Primer used for amplification only 
































Table 3. GenBank ID for Uploaded F Gene Sequences  
GenBank ID: * Description † Gene(s) ‡ Virulence 
JN863120 LaSota M-F LoNDV 
JN863121 New Jersey-Roakin 1946 M-F mNDV 
JN872150 B1 M-F LoNDV 
JN872151 Hitchner M-F LoNDV 
JN872152 Ulster M-F Asymptomatic 
JN872153 Chicken/California/1083(Fontana)/71 M-F vNDV 
JN872154 Beaudette C M-F mNDV 
JN872155 Tennessee 74-2445 M-F NDV 
JN872156 Cormorant Canada M-F Cormorant vNDV 
JN872157 Green Wood Hoope/Eastern 
Hemisphere/5801-22/10 
M-F vNDV 
JN872158 Cormorant/California/24270/97 M-F Cormorant vNDV 
JN872159 Cormorant/Wisconsin/451287-11/06 M-F Cormorant vNDV 
JN872160 Pigeon/Minnesota/511296/07 M-F PPMV-1 
JN872161 Cormorant/Wisconsin/498260-2/07 M-F Cormorant vNDV 
JN872162 Rosella/Belgium/4940/08 M-F vNDV 
JN872163 Chicken/Belize/4224-3/08 M-F vNDV 
JN872164 Chicken/Colombia/440620/06 M-F vNDV 
JN872165 Chicken/Niger/VIR 1377-7/2006 M-F vNDV 
JN872166 Dove/Italy/VIR 24/2008 M-F PPMV-1 
JN872167 Dove/FL/455682-2/2006 M-F PPMV-1 
JN872168 Chicken/Dominican Republic/499-31/2008 M-F vNDV 
JN872169 Pennsylvania/3167/2009 M-F LoNDV 
JN872170 Pigeon/Texas/5254-12/2010 M-F PPMV-1 
JN872171 Turkey/Minnesota/17531-3/2010 M-F LoNDV 
JN872172 Raptor/Minnesota/18575-4/2009 M-F PPMV-1 
JN872173 Pigeon/New York/44407/1984 M-F PPMV-1 
JN872174 New Jersey/9564/2010 M-F PPMV-1 
JN872175 Pigeon/Minnesota/723/2009 M-F PPMV-1 
JN872176 Pheasant/Massachusetts/359425/2005 M-F PPMV-1 
JN872177 Chicken/Massachusetts/344783-3/2004 M-F PPMV-1 
JN872178 Turkey/Louisiana/331309/2004 M-F PPMV-1 
JN872179 Pigeon/Nevada/241851/2003 M-F PPMV-1 
JN872180 Waterfowl/Texas/209682/2002 M-F PPMV-1 
JN872181 Chicken/Honduras/44813/2000 M-F vvNDV 
JN872182 Pigeon/New York/12339/1998 M-F PPMV-1 
JN872183 Pigeon/Maryland/2075/1998 M-F PPMV-1 
JN872184 Pigeon/Wyoming/20210/1997 M-F PPMV-1 
JN872185 Pigeon/New York/32851-2/1995 M-F PPMV-1 
JN872186 Pigeon/Indiana/18002/1991 M-F PPMV-1 
JN872187 Pigeon/Illinois/11748/1993 M-F PPMV-1 
JN872188 Pigeon/Minnesota/2446/1989 M-F PPMV-1 
JN872189 Parrot/Colorado/8278/1982 M-F vvNDV 
JN872190 Pigeon/South Dakota/486839/2007 M-F PPMV-1 
JN872191 Chicken/Texas (GB)/1948 M-F nvNDV 
JN872192 Chicken/California/211472-4/2002 M-F vNDV 
JN872193 Avian/Peru/1918-3/2008 M-F vNDV 
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Table 3. GenBank ID for Uploaded F Gene Sequences Continued 
GenBank ID: * Description † Gene(s) ‡ Virulence 
JN872194 Chicken/Honduras/498109-15/2007 M-F vNDV 
JN942003 Tokyo F NDV 
JN942004 New Jersey/13890-2/2010 F Lineage 6 
JN942005 Muscovy Duck/Pennsylvania/10145/2010 F Lineage 6 
JN942006 New Jersey/32796-2/2009 F Lineage 6 
JN942007 Duck/Pennsylvania/33250/2009 F Lineage 6 
JN942008 Poultry/Florida/31670-4/2009 F Lineage 6 
JN942009 Mallard/Connecticut/17847-2/2009 F Lineage 6 
JN942010 Northern Pintail/Michigan/28171-16/2009 F Lineage 6 
JN942011 Raptor/Minnesota/18575-1/2009 F Lineage 6 
JN942012 Mallard/Wisconsin/22853/2009 F Lineage 6 
JN942013 Mallard/Oregon/13685/2009 F Lineage 6 
JN942014 Wood Duck/Louisiana/2193/2008 F Lineage 6 
JN942015 Mallard/Ohio/2080-2/2008 F Lineage 6 
JN942016 Chicken/Colombia/118-05/2008 F vNDV 
JN942017 Chicken/Colombia/3084-23/2008 F LoNDV 
JN942018 Cormorant/Chile/9138/2007 F vNDV 
JN942019 Avian/Peru/3442-6/2009 F LoNDV 
JN942020 Cormorant/Oregon/399448/2005 F Cormorant vNDV 
JN942021 Cormorant/Nevada/395921/2005 F Cormorant vNDV 
JN942022 Chicken/Texas/309968/2004 F PPMV-1 
JN942023 Cormorant/Oregon/276236-7/2003 F Cormorant vNDV 
JN942024 Cormorant/Wisconsin/272409/2003 F Cormorant vNDV 
JN942025 Cormorant/New York/269385/2003 F Cormorant vNDV 
JN942026 Cormorant/New York/268898-7/2003 F Cormorant vNDV 
JN942027 Fighting Cock/Nicaragua/95066-9/2001 F vvNDV 
JN942028 Chicken/Mexico/51735-8/2000 F vvNDV 
JN942029 Cormorant/Wisconsin/248/1998 F Cormorant vNDV 
JN942030 Cormorant/Wisconsin/28547/1997 F Cormorant vNDV 
JN942031 Chicken/Mexico/37821-2/1996 F vvNDV 
JN942032 Amazon/Missouri/31378/1996 F vvNDV 
JN942033 Avian/Chile/37646/1996 F nvNDV 
JN942034 Ostrich/South America/45445-3/1995 F nNDV 
JN942035 Cormorant/North Dakota/43888-6/1992 F Cormorant vNDV 
JN942036 Turkey/North Dakota/43084-25/1992 F Cormorant vNDV 
JN942037 Cormorant/Minnesota/40140/1992 F Cormorant vNDV 
JN942038 Cormorant/Michigan/38819-5/1992 F Cormorant vNDV 
JN942039 Amazon/California/28936/1988 F vvNDV 
JN942040 Parrot/New Jersey/19674-2/1986 F vvNDV 
JN942041 Cockatoo/Oklahoma/7847/1983 F vvNDV 
JN942042 Amazon/California/16365/1981 F vvNDV 
JN942043 Roller/Tanzania/47385-11/2010 F vNDV 
JN942044 Roller/Tanzania/47387-6/2010 F vNDV 
JN942045 Turkey/Belize/4438-4/2008 F vNDV 
JN941986 Chicken/Honduras/498109/2007 F vNDV 
JN941987 Northern Pintail/Idaho/19663-2/2009 F Lineage 6 
JN967786 Pigeon/New Jersey/58300-4/2000 F PPMV-1 
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Table 3. GenBank ID for Uploaded F Gene Sequences Continued 
GenBank ID: * Description † Gene(s) ‡ Virulence 
JN967787 Pigeon/Illinois/37397/1987 F PPMV-1 
JN967788 Pigeon/Maryland/11936/1985 F PPMV-1 
JN967789 Psittacine/Indiana/29120/1980 F mNDV 
JN941988 Cormorant/Florida/66638/2010 F Cormorant vNDV 
JN941989 Cormorant/Minnesota/1476-7/2008 F Cormorant vNDV 
JN941990 Cormorant/Wisconsin/1675-2/2008 F Cormorant vNDV 
JN941991 Cormorant/Wisconsin/1718/2008 F Cormorant vNDV 
JN941992 Avian/Minnesota/2349/2008 F Cormorant vNDV 
JN941993 Pelican/Wisconsin/2415-02/2008 F Cormorant vNDV 
JN941994 Pigeon/Michigan/1924/2008 F PPMV-1 
JN941995 New York/1989-19/2008 F PPMV-1 
JN941996 Pigeon/Pennsylvania/2062/2008 F PPMV-1 
JN941997 Pigeon/Florida/2181-43/2008 F PPMV-1 
JN941998 Pigeon/Pennsylvania/2282/2008 F PPMV-1 
JN941999 Pigeon/Minnesota/77/2008 F PPMV-1 
JN942000 Dove/Florida/1287/2008 F PPMV-1 
JN942001 Poultry/Colombia/446-00/2008 F vNDV 
JN942002 Chicken/Colombia/2541-05/2008 F LoNDV 
JN942095 Pigeon/Oklahoma/7668/1997 M-F PPMV-1 
JN942096 Duck/Louisiana/36166-35GW/1988 M-F LoNDV 
JN942097 Cormorant/Wisconsin/1926/2008 M-F Cormorant vNDV 
JN942098 Pigeon/North Carolina/56404/2000 M-F PPMV-1 
JN942099 Gannet/Pennsylvania/25017/2000 M-F PPMV-1 
JN942100 Chukar/New Jersey/32429-5/2000 M-F PPMV-1 
JN942101 Finch/Eastern Hemisphere/1409-12/2008 M-F vNDV 
* Strain description in GenBank 
† Gene(s)  M=matrix, M-F=matrix-fusion 
‡ Lo=Low-virulence, M=Mesogenic, VV=Viscerotropic velogenic, NV=Neurotropic velogenic,  



















Table 4. rRT-PCR Primers  
Primer Sequence 5’→3’ * Position 
(bp) 
Primer Pair Amplicon 
size (bp) 
F+4634 5’-TCTCTTGACGGCAGGCCTCTT-3’ 4634-4654 F+4634/F-4795 161 
   F+4634/F-4749d 115 
F+4731 5’-TCAAGTTGCTCCCGAATATGCC-3’ 4731-4752 F+4731/F-4927 196 
F+4778 5’-GCCCCGTTAGAGGCATAC-3’ 4778-4795 F+4778/F-4927 149 
F+4904 5’-ATTATCGGCAGTATAGCTCTTGGG-3’ 4904-4927 F+4904/F-5240 336 
F+5222 5’-TCCCCTGCTCTAACTCAGC-3’ 5222-5240 F+5222/F-5314 92 
F+5291 5’-TTGACTAAATTAGGTGTAGGGAAC-3’ 5291-5314 F+5291/F-5646 355 
F+5625 5’-CCTGTCTGAGCGGCAATACATC-3’ 5625-5646 F+5625/F-5725 100 
F-4795 5’-GTATGCCTCTAACGGGGC-3’ 4778-4795 F+4634/F-4795 161 
F-4927 5’-CCCAAGAGCTATACTGCCGATAAT-3’ 4904-4927 F+4778/F-4927 149 
   F+4731/F-4927 196 
F-5240 5’- GCTGAGTTAGAGCAGGGGA-3’ 5222-5240 F+4904/F-5240 336 
F-5314 5’-GTTCCCTACACCTAATTTAGTCAA-3’ 5291-5314 F+5222/F-5314 92 
F-5646 5’- GATGTATTGCCGCTCAGACAGG-3’ 5625-5646 F+5291/F-5646 355 
F-5725 5’- GCAATTGGCAATAACTGAGCC-3’ 5705-5725 F+5625/F-5725 100 
F+4731d 5’-TCAAGTTGCTCCCGAATAT-3’ 4731-4749 F+4731d/F-4797d 66 
   F+4731d/F-4924d 193 
F+4778d 5’-GCCCCGTTAGAGGCATACAA-3’ 4778-4797 F+4778d/F-4924d 146 
F+4904d 5’-ATTATCGGCAGTATAGCTCTT-3’ 4904-4924 F+4904d/F-5241d 337 
F+5221d 5’-TTCCCCTGCTCTAACTCAGCT-3’ 5221-5241 F+5221d/F-5315d 94 
F+5291d 5’-TTGACTAAATTAGGTGTAGGGAACA-3’ 5291-5315 F+5291d/F-5651d 360 
F+5627d 5’-TGTCTGAGCGGCAATACATCAGCTT-3’ 5627-5651 F+5627d/F-5727d 100 
F-4749d 5’-ATATTCGGGAGCAACTTGA-3’ 4731-4749 F+4634/F-4749d 115 
F-4797d 5’-TTGTATGCCTCTAACGGGGC-3’ 4778-4797 F+4731d/F-4797d 66 
F-4924d 5’-AAGAGCTATACTGCCGATAAT-3’ 4904-4924 F+4778d/F-4924d 146 
   F+4731d/F-4924d 193 
F-5241d 5’-AGCTGAGTTAGAGCAGGGGAA-3’ 5221-5241 F+4904d/F-5241d 337 
F-5315d 5’-TGTTCCCTACACCTAATTTAGTCAA-3’ 5291-5315 F+5221d/F-5315d 94 
F-5651d 5’-AAGCTGATGTATTGCCGCTCAGACA-3’ 5627-5651 F+5291d/F-5651d 360 
F-5727d 5’-TTGCAATTGGCAATAACTGAGCC-3’ 5705-5727 F+5627d/F-5727d 100 




















Figure 1. Conventional RT-PCR Analysis of Initial rRT-PCR Primer Sets 
 
Figure 1. Primer sets were analyzed by conventional RT-PCR and amplicons were visualized on 2% polyacrylamide gel.  
Isolates in each lane are identified by a plus (+) sign.  Minus (-) signs indicate the individual isolate is not present in the 
corresponding lane.    
 
Figure 2. Conventional RT-PCR Analysis of Destabilized rRT-PCR Primers 
 
Figure 2. Primer sets were analyzed by conventional RT-PCR and amplicons were visualized on 2% polyacrylamide gel.  
Isolates in each lane are identified by a plus (+) sign.  Minus (-) signs indicate the individual isolate is not present in the 
corresponding lane. 
 
Figure 3. Conventional RT-PCR Analysis of Final rRT-PCR Primer Sets 
 
Figure 3. Primer sets were analyzed by conventional RT-PCR and amplicons were visualized on 2% polyacrylamide gel.  




CHAPTER 5.  PRIMER DEVELOPMENT FOR AVIAN PARAMYXOVIRUS 
SEROTYPE-1 FUSION GENE CLEAVAGE SITE SEQUENCING 
 
Abstract 
 Molecular diagnostic assays are important tools for determining pathogenicity of 
avian paramyxovirus serotype-1 (APMV-1) isolates.  As gene sequences change over time 
the efficiency of PCR amplification may decrease if the primer sequences are not modified 
accordingly.  Evaluation of the cleavage site sequence of the fusion (F) gene is an important 
method of determining virulence potential.  Genetic variability within the F gene can cause 
difficulty with amplification and sequencing.  A single primer set has been successful for 
amplification of the F gene cleavage site for most strains of APMV-1.  An entirely different 
set of primers must be used to amplify and sequence class I strains of APMV-1.  Here we 
describe evaluation of the matrix (M) and F genes of APMV-1 to design one set of 
amplification and sequencing primers that can be used for all APMV-1 strains.  A single 
amplification primer pair was shown to successfully amplify 99% of the isolates tested.  
Forward and reverse sequencing primers were designed that provided clean, full length F 
gene sequence data for all amplicons produced using the new amplification primer set.    
Introduction  
Avian paramyxovirus serotype-1 (APMV-1) is the causative agent of Newcastle 
disease (ND).  It is a member of the family Paramyxoviridae from the genus Avulavirus 
(1,2,3,4).  APMV-1 is an enveloped, negative sense, single-stranded RNA virus.  The 
genome is non-segmented and encodes at least six proteins including the nucleocapsid (NP), 
phosphoprotein (P), matrix (M), fusion (F), hemagglutinin-neuraminidase (HN) and RNA-
dependent RNA polymerase (L).  Clinical signs can range from asymptomatic to mild 
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respiratory or gastrointestinal disease with infection by low-virulence lentogenic strains.  
Virulent strains can cause severe respiratory or gastrointestinal disease.  Most NDV isolates 
from the U.S. are low-virulence, but virulent strains of NDV have previously been introduced 
into the U.S. through illegally imported birds and cock fighting (1,5).  Double-crested 
cormorants and pigeons are natural reservoirs for two virulent strains of NDV (1,3,6,7,8).  
These virulent NDV (vNDV) strains are primarily restricted to their natural hosts, but each 
has been shown to infect poultry (1).  Analysis of the F gene cleavage site is important to 
monitor viruses for virulence potential.  The presence of multiple basic amino acids at the F 
gene cleavage site and phenylalanine at residue 117 of the F1 protein N-terminus is the 
molecular criteria for determining virulence according to the World Organization for Animal 
Health (1,3,6,9,10).  
Sequencing the F gene cleavage site is an important tool utilized by the National 
Veterinary Services Laboratories (NVSL) to evaluate virulence potential of APMV-1 
isolates.  The ability to quickly evaluate the amino acid sequence of these isolates enhances 
the diagnostic capability of the laboratory.  Unsuccessful amplification attempts or failure to 
obtain quality sequence can delay the characterization of a virus.  This could ultimately result 
in a delayed response to an outbreak of virulent virus.  The current primer set used at the 
NVSL is successful for sequencing most strains of APMV-1 except for class I isolates.  Due 
to sequence variability, mismatches in the primer binding site of class I strains causes a loss 
of binding and lack of amplification using this primer set.  A separate set of primers must be 
used for class I amplification and sequencing.  All APMV-1 isolates are initially amplified 
using the primary set of primers but amplification failure results in a second amplification 
attempt using the class I primer set.  The second amplification primer set is usually 
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successful but repeated amplification attempts wastes resources including personnel time and 
reagents and delays cleavage site analysis.  Here we describe analysis of the M and F gene 
nucleotide sequences of APMV-1 isolates to design universal amplification and sequencing 
primers.  
Materials & Methods  
  Primer design and analysis.  The F gene sequences determined in Chapter 4 were 
analyzeda,b to determine the approximate location of the F gene cleavage site.  M and F gene 
sequences determined in Chapters 3 and 4 were alignedb to identify conserved regions 
surrounding the F gene cleavage site for all strains of APMV-1.  Forward and reverse F gene 
cleavage site amplification primers were chosen from primers found to have high success 
rates in the Chapter 4.  Forward primer F5087f (Table 2 Chapter 4) was synthesizedc in the 
reverse orientation to create amplification primer F-5100.  Forward primer M4094 was also 
utilized from Chapter 4.  These primer sequences were aligned with M and F gene sequences 
in Table 3 of Chapter 3 and Table 3 of Chapter 4 to ensure the primers aligned in the region 
surrounding the cleavage site.  Location of these primers provided complete coverage of the 
cleavage site region.  Amplification efficiency of 95 APMV-1 isolates representing low-
virulence Newcastle disease (ND), mesogenic ND, velogenic neurotropic ND, velogenic 
viscerotropic ND, virulent ND, cormorant virulent ND, pigeon paramyxovirus type-1, and 
class I low-virulence strains were tested using primer set (M4094/F-5100).  Isolates are listed 
in the order they were tested in Table 1, Chapter 5 and primer sequences are listed in Table 2, 
Chapter 5.  Total RNA was extracted as described in Chapter 3 and subjected to RT-PCR 
according to the following parametersd,e: reverse transcription at 50ºC for 30 minutes (min), 
reverse transcriptase inactivation at 95ºC for 15 min, followed by 35 cycles of denaturation at 
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94ºC for 30 seconds (sec), annealing at 45ºC for 30 sec and extension at 72ºC for 1:30 min.  
A final 72ºC for 10 min allowed for additional extension time followed by an infinite hold at 
4ºC.  Amplicons were electrophoresed on a 2% polyacrylamide gel and resulting bands were 
visualizedf (Figure 1).  
The distance between the M4094 binding site and F gene cleavage site is over 800 
nucleotides.  To improve the likelihood of producing clean sequence, a second forward 
primer was created to bind closer to the cleavage site.  M and F gene sequences in Table 3 of 
Chapter 3 and Table 3 of Chapter 4 were aligned to evaluate conserved regions upstream of 
the cleavage site to design a forward primer within 500 nucleotides of the cleavage site.  
Forward primer F+4491 (Table 2 of Chapter 5) was designed to bind the intergenic region 
between the M and F genes which is approximately 429 nucleotides upstream of the cleavage 
site.  Amplicons were taken directly from the amplification step to the sequencing step 
without performing DNA purificationg.  Ninety-four isolates amplified using M4094/F-5100 
were sequencedh with F-5100 and F+4491.  Chromasi files were evaluated to determine if 
clean sequence was obtained for each primer.  Nucleotide sequences were converted to 
amino acid sequencesa and the cleavage site of each isolate was compared to the original 
amino acid sequence obtained during full length F gene sequencing in Chapter 4.   
DNA purification was performed to determine if cleaning the template DNA would 
improve sequence quality for isolates that did not achieve accurate F gene cleavage site 
amino acid sequences during the first attempt.  The DNA of fifteen isolates was purifiedg and 
sequencing was repeated using the primers which gave poor sequence results during initial 
testing.  Three isolates were repeated using F+4491 and 13 isolates were repeated using F-




Sequence alignmentb indicates the F gene cleavage site begins at approximately 
nucleotide position 4920.  As shown in Figure 1, primer pair M4094/F-5100 had good 
amplification for 94 of the 95 isolates tested.  Specimen JN942003 (Figure 1 lane 11) was 
unable to be amplified using these primers.  Sequence alignment showed no mismatches with 
forward primer M4094 while reverse primer F-5100 had six mismatches. 
Clean cleavage site sequence was obtained for approximately 85% of the isolates 
using F+4491.  The primer was unable to provide useable sequence for three isolates.  Eleven 
isolates had sequences that did not appear to be clean in the Chromasi file but the cleavage 
site was accurate when compared to the original cleavage site sequence.  Reverse sequencing 
primer F-5100 also had clean sequence for 85% of the isolates.  The remaining 14 isolates 
had clean sequence except in the approximately 15-20 nucleotide region spanning the 
cleavage site. 
Purified DNA had clean sequence for all three isolates repeated using F+4491 and all 
13 isolates repeated using F-5100, including the region spanning the cleavage site.  When 
converted to amino acid sequence, all 16 isolates had F gene cleavage sites matching their 
original amino acid sequence obtained during full length F gene sequencing in Chapter 4.   
Discussion 
The inability of the current APMV-1 primer set to amplify and sequence all APMV-1 
isolates led to the interest in developing a new primer set to prevent repeated amplification 
attempts during F gene cleavage site sequencing.  M and F gene sequences, obtained in 
Chapters 3 and 4, were available to analyze the region surrounding the F gene cleavage site 
for primer development.  Primers M4094 and F-5100 were very successful in the previous 
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two studies and together they encompassed the cleavage site.  Despite the fact that one isolate 
was unable to be amplified, additional primers were not designed due to the 99% success 
rate.  Lack of amplification for specimen JN942003 was not surprising given this isolate was 
also unable to be amplified in cleavage site region in Chapter 4.  The presence of six 
mismatches in the reverse primer F-5100 likely caused the lack of amplification for this 
isolate in both studies.  All primer sequences were originally designed with two or less 
mismatches to the target strains in order to optimize binding potential.  Test sensitivity has 
been shown to decrease by three to four logs of virus when three to four mismatches are 
present in the primer (11,12,13).  This is supported by the fact that despite the lack of 
mismatches in the forward primer, six mismatches in the reverse primer resulted in a 
complete lack of amplification.  
The location of M4094 was too far from the cleavage site to be useful as a sequencing 
primer.  The M and F genes were again analyzed to determine if a conserved site existed 
closer to the cleavage site to design a new forward primer.  Forward primer F4487f was 
relatively successful in Chapter 4 (see Chapter 4 Table 2).  To improve the efficiency of this 
primer, four nucleotides were removed from the 5’ end to form F+4491.  This primer binds 
the conserved intergenic region between the M and F genes.  Proximity to the cleavage site 
made this location highly desirable as a sequencing primer.  This primer should not be used 
as an amplification primer because the run of adenines in the primer sequence may allow it to 
bind non-specifically to other regions of the genome.   
Even without DNA purification, clean cleavage site sequence was obtained for 
approximately 85% of the isolates using both F+4491 and F-5100.  Eleven isolates had good 
sequences with F+4491 but their peaks in the Chromasi files were not as clean as the 
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remainder of the isolates.  DNA purification was not performed on these isolates because 
their cleavage site amino acid sequences were accurate when compared to their sequences in 
Chapter 4.  DNA purification greatly improved the quality of the sequence for all isolates that 
were retested.  It is recommended that all amplicons produced from M4094/F-5100 should be 
DNA purified prior to sequencing with either F+4491 or F-5100.  In summary, the 
amplification primers (M4094/F-5100) developed in this study were able to successfully 
amplify 99% of the 95 isolates tested.  Clean, full length sequence was achieved for all 
amplicons using the F+4491 and F-5100 sequencing primers.  The outcome of this study 
yielded universal amplification and sequencing primers that can be used to sequence the F 
gene cleavage site for all strains of APMV-1.     
 
Sources and Manufacturers 
a. SeqBuilder, DNAStar Lasergene 8, Madison, WI. 
 
b. Sequencher® version 4.9 sequence analysis software, Gene Codes Corporation, Ann 
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d. Qiagen® One-Step RT-PCR Enzyme Kit, Qiagen®, Valencia, CA. 
 
e. GeneAmp® PCR System 9700, Applied Biosystems™, Foster City, CA. 
 
f. AlphaImager™ 2200, Alpha Innotech, Miami, FL. 
 
g. QIAquick® PCR Purification Kit (250), Qiagen®Sciences, Maryland. 
 
h. 3500XL Genetic Analyzer, Applied Biosystems™, Foster City, CA. 
 
i. Chromas Version 1.45, Conor McCarthy, School of Health Sciences Griffith 
University, Southport, Queensland Australia.  
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Tables and Figures 
Table 1. F Gene Cleavage Site Sequencing Isolates 
GenBank ID: * Description † Gene(s) ‡ Virulence 
JN863120 LaSota M-F LoNDV 
JN863121 New Jersey-Roakin 1946 M-F mNDV 
JN872150 B1 M-F LoNDV 
JN872151 Hitchner M-F LoNDV 
JN872152 Ulster M-F Asymptomatic 
JN872191 Chicken/Texas (GB)/1948 M-F nvNDV 
JN872153 Chicken/California/1083(Fontana)/71 M-F vNDV 
JN872154 Beaudette C M-F mNDV 
JN872155 Tennessee 74-2445 M-F NDV 
JN872156 Cormorant Canada M-F Cormorant vNDV 
JN942003 Tokyo F NDV 
JN872157 Green Wood Hoope/Eastern 
Hemisphere/5801-22/10 
M-F vNDV 
JN872192 Chicken/California/211472-4/2002 M-F vNDV 
JN872158 Cormorant/California/24270/97 M-F Cormorant vNDV 
JN872159 Cormorant/Wisconsin/451287-11/06 M-F Cormorant vNDV 
JN872160 Pigeon/Minnesota/511296/07 M-F PPMV-1 
JN872161 Cormorant/Wisconsin/498260-2/07 M-F Cormorant vNDV 
JN872194 Chicken/Honduras/498109-15/2007 M-F vNDV 
JN872162 Rosella/Belgium/4940/08 M-F vNDV 
JN872163 Chicken/Belize/4224-3/08 M-F vNDV 
JN942097 Cormorant/Wisconsin/1926/2008 M-F Cormorant vNDV 
JN872193 Avian/Peru/1918-3/2008 M-F vNDV 
JN942101 Finch/Eastern Hemisphere/1409-12/2008 M-F vNDV 
JN872168 Chicken/Dominican Republic/499-31/2008 M-F vNDV 
JN872190 Pigeon/South Dakota/486839/2007 M-F PPMV-1 
JN872167 Dove/FL/455682-2/2006 M-F PPMV-1 
JN872164 Chicken/Colombia/440620/06 M-F vNDV 
JN872165 Chicken/Niger/VIR 1377-7/2006 M-F vNDV 
JN872166 Dove/Italy/VIR 24/2008 M-F PPMV-1 
JN872173 Pigeon/New York/44407/1984 M-F PPMV-1 
JN942019 Avian/Peru/3442-6/2009 F LoNDV 
JN942020 Cormorant/Oregon/399448/2005 F Cormorant vNDV 
JN942021 Cormorant/Nevada/395921/2005 F Cormorant vNDV 
JN872176 Pheasant/Massachusetts/359425/2005 M-F PPMV-1 
JN872177 Chicken/Massachusetts/344783-3/2004 M-F PPMV-1 
JN872178 Turkey/Louisiana/331309/2004 M-F PPMV-1 
JN942022 Chicken/Texas/309968/2004 F PPMV-1 
JN942023 Cormorant/Oregon/276236-7/2003 F Cormorant vNDV 
JN942024 Cormorant/Wisconsin/272409/2003 F Cormorant vNDV 
JN942025 Cormorant/New York/269385/2003 F Cormorant vNDV 
JN942026 Cormorant/New York/268898-7/2003 F Cormorant vNDV 
JN872179 Pigeon/Nevada/241851/2003 M-F PPMV-1 
JN872180 Waterfowl/Texas/209682/2002 M-F PPMV-1 
JN967786 Pigeon/New Jersey/58300-4/2000 F PPMV-1 
110 
 
Table 1. F Gene Cleavage Site Sequencing Isolates Continued 
GenBank ID: * Description † Gene(s) ‡ Virulence 
JN942027 Fighting Cock/Nicaragua/95066-9/2001 F vvNDV 
JN942098 Pigeon/North Carolina/56404/2000 M-F PPMV-1 
JN942028 Chicken/Mexico/51735-8/2000 F vvNDV 
JN872181 Chicken/Honduras/44813/2000 M-F vvNDV 
JN942100 Chukar/New Jersey/32429-5/2000 M-F PPMV-1 
JN942099 Gannet/Pennsylvania/25017/2000 M-F PPMV-1 
JN872182 Pigeon/New York/12339/1998 M-F PPMV-1 
JN872183 Pigeon/Maryland/2075/1998 M-F PPMV-1 
JN942029 Cormorant/Wisconsin/248/1998 F Cormorant vNDV 
JN942030 Cormorant/Wisconsin/28547/1997 F Cormorant vNDV 
JN872184 Pigeon/Wyoming/20210/1997 M-F PPMV-1 
JN942095 Pigeon/Oklahoma/7668/1997 M-F PPMV-1 
JN942031 Chicken/Mexico/37821-2/1996 F vvNDV 
JN942032 Amazon/Missouri/31378/1996 F vvNDV 
JN942033 Avian/Chile/37646/1996 F nvNDV 
JN942034 Ostrich/South America/45445-3/1995 F nNDV 
JN872185 Pigeon/New York/32851-2/1995 M-F PPMV-1 
JN872186 Pigeon/Indiana/18002/1991 M-F PPMV-1 
JN872187 Pigeon/Illinois/11748/1993 M-F PPMV-1 
JN942035 Cormorant/North Dakota/43888-6/1992 F Cormorant vNDV 
JN942007 Duck/Pennsylvania/33250/2009 F Lineage 6 
JN941987 Northern Pintail/Idaho/19663-2/2009 F Lineage 6 
JN942004 New Jersey/13890-2/2010 F Lineage 6 
JN942005 Muscovy Duck/Pennsylvania/10145/2010 F Lineage 6 
JN942006 New Jersey/32796-2/2009 F Lineage 6 
JN942008 Poultry/Florida/31670-4/2009 F Lineage 6 
JN942010 Northern Pintail/Michigan/28171-16/2009 F Lineage 6 
JN942012 Mallard/Wisconsin/22853/2009 F Lineage 6 
JN942009 Mallard/Connecticut/17847-2/2009 F Lineage 6 
JN942013 Mallard/Oregon/13685/2009 F Lineage 6 
JN942014 Wood Duck/Louisiana/2193/2008 F Lineage 6 
JN942015 Mallard/Ohio/2080-2/2008 F Lineage 6 
JN942011 Raptor/Minnesota/18575-1/2009 F Lineage 6 
JN872169 Pennsylvania/3167/2009 M-F LoNDV 
JN872170 Pigeon/Texas/5254-12/2010 M-F PPMV-1 
JN872171 Turkey/Minnesota/17531-3/2010 M-F LoNDV 
JN872174 New Jersey/9564/2010 M-F PPMV-1 
JN872175 Pigeon/Minnesota/723/2009 M-F PPMV-1 
JN942043 Roller/Tanzania/47385-11/2010 F vNDV 
JN942044 Roller/Tanzania/47387-6/2010 F vNDV 
JN942045 Turkey/Belize/4438-4/2008 F vNDV 
JN941988 Cormorant/Florida/66638/2010 F Cormorant vNDV 
JN941989 Cormorant/Minnesota/1476-7/2008 F Cormorant vNDV 
JN941990 Cormorant/Wisconsin/1675-2/2008 F Cormorant vNDV 
JN941991 Cormorant/Wisconsin/1718/2008 F Cormorant vNDV 
JN941992 Avian/Minnesota/2349/2008 F Cormorant vNDV 
JN872172 Raptor/Minnesota/18575-4/2009 M-F PPMV-1 
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Table 1. F Gene Cleavage Site Sequencing Isolates Continued 
GenBank ID: * Description † Gene(s) ‡ Virulence 
JN941994 Pigeon/Michigan/1924/2008 F PPMV-1 
JN941995 New York/1989-19/2008 F PPMV-1 
§N/A Guinea Fowl/Alabama/53177-1/11 N/A LoNDV 
§N/A Turkey/Alabama/54568-1/11 N/A LoNDV 
* Strain description in GenBank 
† Gene(s)  M=matrix, M-F=matrix-fusion 
‡ Lo=Low-virulence, M=Mesogenic, VV=Viscerotropic velogenic, NV=Neurotropic velogenic,  
N=Neurotropic, V=Virulent, Lineage 6=Class I 





Table 2. Sequencing and Amplification Primers 
Primer Sequence 5’→3’ ‡ Position (bp) Amplicon size (bp) 
*M4094 5’-GGGCTCAGTGATGTGCT-3’ 4094-4110 1006 
*F-5100 5’ CAAACTGCTGCATCTTCCC-3’ 5081-5100 1006 
†F+4491 5’-AAAAAACACGGGTAGA-3’ 4491-4508  
* Primer used for amplification only 
†Primer used for sequencing only 




Figure 1. Amplification Primer Conventional RT-PCR Analysis  
 
Figure 1. Primer set was analyzed by conventional RT-PCR and amplicons were visualized on 2% polyacrylamide gel with 
a 1KB ladderj.  Expected amplicon size is 1006bp.  Isolates in each lane appear in descending order according to Table 1, 
with the gel on the left containing isolates 1-58 and the gel on the right containing isolates 59-95 followed by one lane 




CHAPTER 6.  GENERAL CONCLUSIONS 
 APMV-1 affects all orders of avian species and has a world-wide distribution.  
Disease severity is dependent on several factors including route of inoculation, host species 
and pathogenicity of the virus strain.  Virulent strains can cause great economic loss to the 
agricultural community.  Maintaining up-to-date diagnostic assays is important for passive 
surveillance including mortality events and foreign animal disease diagnostic investigations.  
Similarities in clinical signs to other avian diseases and ease of viral transmission emphasize 
the need for rapid and accurate diagnosis.  Classical diagnostic methods such as virus 
isolation can be time consuming leading to a delay in viral identification and 
characterization.  Molecular methods including rRT-PCR assays and sequencing techniques 
are rapid methods for identifying and pathotyping viruses based on their genetic 
characteristics.  Genetic diversity can limit value of molecular assays if primer design does 
not keep up with changes in viral sequence over time.   
Small genomic changes resulting from replication errors can result in alterations in 
virulence.  The introduction of basic amino acids in the fusion gene cleavage site, for 
example, can grant the virus ability to replicate systemically and cause severe disease.  
Molecular changes should be monitored to analyze alterations in the cleavage site which can 
identify a potential increase in virulence.  Sequencing and rRT-PCR assays remain important 
diagnostic tools for monitoring viral changes.  Molecular assays should be continually 
modified to maintain the ability to detect all strains of APMV-1.  
 Differentiation between virulent and low-virulence strains of APMV-1 is also 
important to recognize and respond to introductions of virulent viruses into the U.S.  Real-
time RT-PCR assays play an important role in detecting virulent strains of APMV-1.  The 
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ability to detect vNDV introduction in poultry remains a priority for diagnostic laboratories.  
Despite the inability to produce an rRT-PCR assay specific for the cormorant vNDV and 
PPMV-1 strains of APMV-1, continued analysis of the fusion gene may lead to development 
of an rRT-PCR assay with the ability to detect all strains of vNDV.     
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